Page last updated: 2024-12-11

ppi-0903

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ceftaroline : A cephalosporin that is the active metabolite of the prodrug ceftaroline fosamil. Used for the treatment of adults with acute bacterial skin and skin structure infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID Source	ID
PubMed CID	9852981
CHEMBL ID	501122
CHEBI ID	70718
SCHEMBL ID	1464037
MeSH ID	M0504765

Synonyms (36)

Synonym
CHEMBL501122
ceftaroline fosamil anhydrous
chebi:70718 ,
SCHEMBL1464037
pyridinium, 4-(2-(((6r,7r)-2-carboxy-7-(((2z)-2-(ethoxyimino)-1-oxo-2-(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)ethyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)thio)-4-thiazolyl)-1-methyl-, inner salt
unii-7p6fqa5d21
ceftaroline inner salt
ceftaroline
ceftaroline fosamil [usan:inn:ban]
7p6fqa5d21 ,
ppi0903
229016-73-3
7-({(2z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl}amino)-3-{[4-(1-methylpyridinium-4-yl)-1,3-thiazol-2-yl]sulfanyl}-3,4-didehydrocepham-4-carboxylate
ceftarolina fosamilo
(6r,7r)-7-({(2z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl}amino)-3-{[4-(1-methylpyridinium-4-yl)-1,3-thiazol-2-yl]sulfanyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
ceftarolinum fosamilum
DB06590
(6r,7r)-7-[(2z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DTXSID60177444 ,
bdbm50482776
ceftaroline fosamil inner salt
pyridinium, 4-[2-[[(6r,7r)-2-carboxy-7-[[(2z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-methyl-, inner salt
(6r,7r)-7-[[(2z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
ceftaroline fosamil (inner salt)
HY-14738
CS-0003529
pyridinium, 4-(2-(((6r,7r)-2-carboxy-7-(((2z)-2-(ethoxyimino)-1-oxo-2-(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)ethyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)thio)-4-thiazolyl)-1-methyl-
dtxcid1099935
(6r,7r)-7-(((2z)-2-(ethoxyimino)-2-(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)acetyl)amino)-3-((4-(1-methylpyridinium-4-yl)-1,3-thiazol-2-yl)sulfanyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
(6r,7r)-7-((2z)-2-ethoxyimino-2-(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)acetyl)amino)-3-(4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl)sulfanyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
j01di02
7-(((2z)-2-(ethoxyimino)-2-(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)acetyl)amino)-3-((4-(1-methylpyridinium-4-yl)-1,3-thiazol-2-yl)sulfanyl)-3,4-didehydrocepham-4-carboxylate
(6r,7r)-7-(((2z)-(ethoxyimino)(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)acetyl)amino)-3-((4-(1-methylpyridinium-4-yl)thiazol-2-yl)sulfanyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carboxylate
4-(2-{[(6r,7r)-2-carboxylato-7-[(2z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]sulfanyl}-1,3-thiazol-4-yl)-1-methylpyridin-1-ium
EN300-21831212
AKOS040757525

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" Increasing antimicrobial resistance in cSSSI has led to a need for new safe and effective therapies."	( Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Baculik, T; Corey, GR; Critchley, I; Das, AF; Friedland, HD; Talbot, GH; Thye, D; Wilcox, M; Witherell, GW, 2010)	0.36
" The rates of adverse events, discontinuations because of an adverse event, serious adverse events, and death also were similar between treatment groups."	( Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Baculik, T; Corey, GR; Critchley, I; Das, AF; Friedland, HD; Talbot, GH; Thye, D; Wilcox, M; Witherell, GW, 2010)	0.36
" Ceftaroline and ceftriaxone were well tolerated; rates of adverse events, serious adverse events, deaths, and premature discontinuations caused by an adverse event were similar in both treatment arms."	( Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Critchley, I; Eckburg, PB; File, TM; Friedland, HD; Lee, J; Llorens, L; Low, DE; Talbot, GH; Thye, D, 2010)	0.36
" Equally important is the need to provide therapy that is safe and well tolerated."	( Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. Corrado, ML, 2010)	0.36
" All patients were followed for treatment-emergent adverse events (TEAEs) occurring from the start of the initial study drug infusion up to the test-of-cure visit, ∼1 week following the last dose of study medication; serious adverse events (SAEs) that occurred within 30 days after the last dose were recorded."	( Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. Corrado, ML, 2010)	0.36
" Clinical cure, microbiological response, adverse events (AEs) and laboratory tests were assessed."	( FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. Critchley, IA; Eckburg, PB; File, TM; Friedland, HD; Lee, J; Llorens, L; Low, DE; Talbot, GH; Thye, DA, 2011)	0.37
" Clinical cure, microbiological response, adverse events (AEs) and laboratory tests were assessed."	( FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. Critchley, IA; David Friedland, H; Eckburg, PB; File, TM; Lee, J; Llorens, L; Low, DE; Talbot, GH; Thye, DA, 2011)	0.37
" All patients were followed for treatment-emergent adverse events (TEAEs) occurring from the start of the initial study drug infusion up to the test-of-cure visit; serious adverse events (SAEs) including deaths occurring up to the late follow-up visit or within 30 days after the last dose were additionally recorded."	( Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. Friedland, HD; Laudano, JB; Rank, DR, 2011)	0.37
" Infusions of ceftaroline fosamil/avibactam were well tolerated at total daily doses of up to 1,800 mg of each compound, and all adverse events (AEs) were mild to moderate in severity."	( Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Rank, D; Riccobene, TA; Su, SF, 2013)	0.39
" While on ceftaroline, adverse events were experienced in 8% (41/527) of the patients and 9% (28/307) were readmitted within 30 days after discharge for the same infection."	( Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Barber, KE; Barr, VO; Casapao, AM; Davis, SL; Goff, DA; Kaye, KS; Klinker, KP; Molloy, LM; Mynatt, RP; Pogue, JM; Rybak, MJ, 2014)	0.4
"Ceftaroline was discontinued in 9 (75%) of 12 patients secondary to adverse effects."	( High incidence of discontinuations due to adverse events in patients treated with ceftaroline. Chan, JD; Dellit, TH; Jain, R; Lynch, JB; Pottinger, PS; Rogers, L, 2014)	0.4
"When given for off-label indications to 12 patients at our institutions, ceftaroline was associated with an unexpectedly high rate (75%) of discontinuation due to perceived adverse events, including hematologic toxicities and rash."	( High incidence of discontinuations due to adverse events in patients treated with ceftaroline. Chan, JD; Dellit, TH; Jain, R; Lynch, JB; Pottinger, PS; Rogers, L, 2014)	0.4
" The most frequent adverse events were rash/drug eruption, most of which were of mild-moderate intensity and considered related to treatment."	( Evaluation of the pharmacokinetics and safety of single and multiple ceftaroline fosamil infusions in healthy Chinese and Western subjects. Edeki, T; Li, H; Li, J; Sunzel, M; Wilson, D; Xu, P; Yang, L, 2015)	0.42
" Safety assessments were treatment-emergent adverse events, and the effectiveness of treatment was assessed by clinical and microbiologic outcomes."	( A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia. Blumer, JL; Bradley, JS; Cannavino, C; Friedland, HD; Ghonghadze, T; Jandourek, A; O'Neal, T, 2016)	0.43
" At least one treatment-emergent adverse event was experienced by 12/30 patients (40%) in the ceftaroline fosamil group and 8/10 (80%) in the comparator group; most treatment-emergent adverse events in both groups were mild to moderate in intensity."	( A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia. Blumer, JL; Bradley, JS; Cannavino, C; Friedland, HD; Ghonghadze, T; Jandourek, A; O'Neal, T, 2016)	0.43
" Rates of study drug-related treatment-emergent adverse events were similar for ceftaroline fosamil [22% (23/106)] and comparator [23% (12/53)]."	( A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection. Antadze, T; Bradley, JS; Giorgobiani, M; Jandourek, A; Korczowski, B; O'Neal, T; Smith, A; Stryjewski, ME, 2016)	0.43
"The pattern and incidence of adverse events were similar between the q8h and q12h ceftaroline fosamil pools."	( Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h. Cheng, K; Hammond, J; Pypstra, R; Yan, JL, 2019)	0.51
" The rate of therapeutic failure was used to determine the effectiveness, while the presence of any adverse event was considered for safety."	( Safety and effectiveness of ceftaroline fosamil in children: a systematic review and meta-analysis. Lede, R; Rosanova, MT; Sberna, N, 2019)	0.51
" Ten adverse events (AEs) occurred in 5 (45."	( Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis. Bradley, JS; Chan, PLS; Hammond, J; Hendrick, VM; Leister-Tebbe, HK; Mas Casullo, V; Raber, SR; Riccobene, T; Stone, GG; Yan, JL, 2020)	0.56
" We report 11 successes and no severe adverse drug reactions."	( Safety and Efficacy of Ceftaroline in Neonates With Staphylococcal Late-onset Sepsis: A Case Series Analysis. Butin, M; Callies, A; Crémet, L; Flamant, C; Gély, L; Gregoire, M; Guillouzouic, A; Launay, E; Martin-Perceval, L; Prot-Labarthe, S; Ruellan, AL; Verdier, MC, 2023)	0.91

Pharmacokinetics

Excerpt	Reference	Relevance
"This study assessed the pharmacokinetic profiles for intramuscular and intravenous ceftaroline treatment for rats, rabbits, and monkeys."	( Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection. Ge, Y; Maynard, D; Rickert, DE, 2010)	0.36
" The pharmacokinetics for ceftaroline fosamil are straightforward and reminiscent of many other cephalosporin antibiotics, with a terminal half-life of ∼2."	( Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity. Drusano, GL, 2010)	0.36
" Dose fractionation experiments identified that "time > threshold" was the pharmacodynamic index linked to cell kill and resistance suppression."	( Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Brown, D; Castanheira, M; Critchley, I; Drusano, GL; Grasso, C; Jones, RN; Kulawy, R; Liu, W; Louie, A; Thye, D; Vanscoy, B; Williams, G, 2012)	0.38
"This study assessed the pharmacodynamics of ceftaroline against penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model."	( Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model. Adam, H; Hoban, DJ; Karlowsky, JA; Nichol, K; Noreddin, AM; Yachison, C; Zhanel, GG, 2012)	0.38
" No significant differences in systemic exposure of ceftaroline or avibactam were observed when the drugs were administered alone versus concomitantly, indicating that there was no apparent pharmacokinetic interaction between ceftaroline fosamil and avibactam administered as a single dose."	( Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Rank, D; Riccobene, TA; Su, SF, 2013)	0.39
" A population pharmacokinetic (PPK) model for ceftaroline was developed in NONMEM® using data from 185 healthy subjects and 92 patients with acute bacterial skin and skin structure infection (ABSSSI)."	( Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. Ambrose, PG; Bhavnani, SM; Forrest, A; Khariton, T; Reynolds, DK; Riccobene, T; Rubino, CM; Van Wart, SA, 2013)	0.39
" The objective of the studies presented herein was to establish the pharmacokinetic profile of ceftaroline in healthy subjects and special populations of interest, such as elderly subjects, subjects with renal impairment, or subjects with end-stage renal disease on intermittent hemodialysis."	( A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis. Jakate, A; Rank, D; Riccobene, T, 2014)	0.4
" The pharmacokinetic parameters of ceftaroline administered through the intramuscular route in diverse animal species were similar to those observed when the drug was administered intravenously and consequently clinical research into ceftaroline administered through this alternative route would be appropriate."	( [Pharmacokinetics and pharmacodynamics of ceftaroline]. Grau, S; Luque, S; Sorlí, L, 2014)	0.4
" Blood samples for pharmacokinetic analysis were taken over 24 h."	( Safety, local tolerability and pharmacokinetics of ceftaroline fosamil administered in a reduced infusion volume. Broadhurst, H; Edeki, T; Kujacic, M; Li, J; Sunzel, M, 2014)	0.4
"This review covers the mechanism of action; bacterial resistance; pharmacokinetic characteristics in various patient populations; pharmacodynamic data in animal and in vitro models as well as human studies; efficacy observed in clinical trials for ABSSSI and CABP; and adverse effects."	( Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil. Danziger, LH; Glowacki, RC; Merker, A; Rodvold, KA, 2014)	0.4
" Pharmacokinetic and microbiological data were obtained from the literature."	( Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function. Canut, A; Isla, A; Rodríguez-Gascón, A, 2015)	0.42
"The pharmacokinetic profile of ceftaroline has not been well characterized in obese adults."	( Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects. Danziger, LH; Justo, JA; Mayer, SM; Novak, RM; Pai, MP; Rodvold, KA; Soriano, MM, 2015)	0.42
" 4-7 L/h after multiple dosing) approximates glomerular filtration rate, with a terminal half-life of ~2."	( A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline. Ensom, MH; Kiang, TK; Wilby, KJ, 2015)	0.42
" Blood (pre- and post-haemodialysis) and dialysate samples were obtained for pharmacokinetic analysis."	( An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis. Edeki, T; Learoyd, M; Li, J; Li, Y; Ngo, N; Sunzel, M, 2015)	0.42
" After an interim analysis of the first four patients' pharmacokinetic data, the remaining four patients received a change in dosage of ceftaroline to 600 mg every 8 hours."	( Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis. Anstead, MI; Autry, EB; Burgess, DR; Gardner, BM; Kuhn, RJ; Leung, NR; Rybak, JM, 2016)	0.43
" These ceftaroline concentrations were used to estimate patient-specific pharmacokinetic parameters, and 10,000-patient Monte Carlo simulations were performed to determine the pharmacodynamic probability of target attainment (PTA) for ceftaroline in adults with CF."	( Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis. Anstead, MI; Autry, EB; Burgess, DR; Gardner, BM; Kuhn, RJ; Leung, NR; Rybak, JM, 2016)	0.43
"A range of fT>MIC values (0%-100%) were simulated over 96 h using a single-compartment dilutional in vitro pharmacokinetic model using Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter koseri and Serratia marcescens (n = 16)."	( Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection. Bowker, KE; MacGowan, AP; Noel, AR; Tomaselli, S, 2016)	0.43
"Using an in vitro pharmacokinetic model we simulated human drug concentration-time courses associated with ceftaroline 600 mg every 8 h and ceftazidime 2000 mg every 8 h."	( The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection. Bowker, K; MacGowan, A; Noel, A; Tomaselli, S, 2017)	0.46
"As AUC is a much easier and more reliable pharmacokinetic measure than C max , it would be useful to explore how AUC-based indices for avibactam exposures could be used for translating the results of the present study into patients' therapy."	( The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection. Bowker, K; MacGowan, A; Noel, A; Tomaselli, S, 2017)	0.46
" This dose of ceftaroline was adequate to achieve the pharmacodynamic endpoint associated with efficacy for methicillin-resistant Staphyloccocus aureus."	( Pharmacokinetics of Ceftaroline in a Preterm Infant With Methicillin-Resistant Staphylococcus Aureus Pneumonia. Bernhardt, J; Gonzalez, D; Jhaveri, R; Laughon, M; Massaro, M; Salerno, SN, 2018)	0.48
" The objective of this study was to determine the pharmacokinetic and pharmacodynamic profile of IV ceftaroline in patients with CF."	( Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. Barsky, EE; Goobie, SM; McAdam, AJ; Pereira, LM; Priebe, GP; Sawicki, GS; Sullivan, KJ; Wong, A, 2018)	0.48
" Maximum plasma concentration, systemic clearance, and elimination half-life were calculated."	( Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. Barsky, EE; Goobie, SM; McAdam, AJ; Pereira, LM; Priebe, GP; Sawicki, GS; Sullivan, KJ; Wong, A, 2018)	0.48
" Six of seven patients (86%) demonstrated an increase in volume of distribution, five of seven patients (71%) demonstrated an increase in clearance, and 100% of patients demonstrated a shorter half-life estimate as compared with the package insert estimate."	( Ceftaroline for Suspected or Confirmed Invasive Methicillin-Resistant Staphylococcus aureus: A Pharmacokinetic Case Series. Chopra, A; Cies, JJ; Enache, A; Moore, WS, 2018)	0.48
" A higher mg/kg dose and a more frequent dosing interval for ceftaroline may be needed in PICU patients to provide appropriate pharmacodynamic exposures."	( Ceftaroline for Suspected or Confirmed Invasive Methicillin-Resistant Staphylococcus aureus: A Pharmacokinetic Case Series. Chopra, A; Cies, JJ; Enache, A; Moore, WS, 2018)	0.48
" A two-step compartmental pharmacokinetic analysis was conducted."	( Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with an external ventricular drain. Bouhemad, B; Chauzy, A; Chavanet, P; Combes, JC; Couet, W; Defrance, N; Nadji, A, 2019)	0.51
" The Cmax was 18."	( Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with an external ventricular drain. Bouhemad, B; Chauzy, A; Chavanet, P; Combes, JC; Couet, W; Defrance, N; Nadji, A, 2019)	0.51
" In silico pharmacodynamic models based on stochastic simulations (Monte Carlo) are important tools to estimate best antimicrobial regimens in different scenarios."	( Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration. Cuba, GT; da Costa, TM; Dos Santos, KRN; Kiffer, CRV; Morgado, PGM; Nicolau, DP; Nouér, SA, 2020)	0.56
" Pharmacokinetic samples were collected via sparse-sampling protocol."	( Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis. Bradley, JS; Chan, PLS; Hammond, J; Hendrick, VM; Leister-Tebbe, HK; Mas Casullo, V; Raber, SR; Riccobene, T; Stone, GG; Yan, JL, 2020)	0.56
" This study aimed to propose proper ceftaroline dosages optimized for the renally impaired pediatric population using physiologically based pharmacokinetic (PBPK) modeling."	( Ceftaroline Dosage Optimized for Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling. Guo, G; Huang, P; Ke, M; Lin, C; Wu, W; Xu, J; Ye, L; You, X; Zhou, J, 2021)	0.62
"A population pharmacokinetic model was developed using pharmacokinetic data from 18 patients with measured creatinine clearance (CLCR) ranging between 83 and 309 mL/min."	( Population pharmacokinetic/pharmacodynamic study suggests continuous infusion of ceftaroline daily dose in ventilated critical care patients with early-onset pneumonia and augmented renal clearance. Ashenoune, K; Boisson, M; Chauzy, A; Couet, W; Dahyot-Fizelier, C; Ferrandière, M; Gregoire, N; Lasocki, S; Marchand, S; Mimoz, O; Seguin, P, 2022)	0.72
"Physiologically based pharmacokinetic models were developed from pharmacokinetic studies of healthy adults, geriatric, paediatric, obese and RI patients."	( Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations. Annaert, P; Martins, FS; Martins, JES; Severino, P; Sy, SKB, 2023)	0.91
"Our work illustrates how physiologically based pharmacokinetic modelling can inform appropriate dosing of adult and paediatric patients and thereby enable prediction of target attainment in the patients during multitherapies."	( Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations. Annaert, P; Martins, FS; Martins, JES; Severino, P; Sy, SKB, 2023)	0.91

Compound-Compound Interactions

Excerpt	Reference	Relevance
"Ceftaroline exhibits in vitro activity against extended-spectrum β-lactamase (ESBL)-, AmpC-, and KPC-producing Enterobacteriaceae when combined with the novel β-lactamase inhibitor NXL104."	( In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Crandon, JL; Furtado, GH; Nicolau, DP; Williams, G; Wiskirchen, DE, 2011)	0.37
" In this evaluation, we examined organisms carrying defined β-lactamases and identified doses and schedules of NXL104 in combination with the new cephalosporin ceftaroline, which would maintain good bacterial cell kill and suppress resistance emergence for a clinically relevant period of 10 days in our hollow-fiber infection model."	( Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Brown, D; Castanheira, M; Critchley, I; Drusano, GL; Grasso, C; Jones, RN; Kulawy, R; Liu, W; Louie, A; Thye, D; Vanscoy, B; Williams, G, 2012)	0.38
"This study was conducted to determine the safety, tolerability, and pharmacokinetics of intravenous doses of ceftaroline fosamil administered in combination with the novel non-β-lactam β-lactamase inhibitor avibactam in healthy adults."	( Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Rank, D; Riccobene, TA; Su, SF, 2013)	0.39
" Avibactam, a non-β-lactam β-lactamase inhibitor, has been combined with ceftaroline or ceftazidime but these two combinations have not been directly compared."	( The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection. Bowker, K; MacGowan, A; Noel, A; Tomaselli, S, 2017)	0.46

Bioavailability

Excerpt	Reference	Relevance
" This new quinazolinone has potent activity against methicillin-resistant (MRSA) strains, low clearance, oral bioavailability and shows efficacy in a mouse neutropenic thigh infection model."	( Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials. Bastian, M; Bouley, R; Chang, M; Ding, D; Lastochkin, E; Mobashery, S; Peng, Z; Schroeder, VA; Song, W; Suckow, MA; Wolter, WR, 2016)	0.43
" A bioavailability test was also conducted to observe the optimal rate of CF elution from the graft."	( Ceftaroline fosamil laden allograft: A new modality in reducing infection? Haseeb, A; Ju, CTS; Sim, LH; Singh, VA, )	0.13

Dosage Studied

Excerpt	Relevance	Reference
" Based on Monte Carlo simulations, dosage adjustment is recommended for patients with moderate renal impairment (creatinine clearance 30-50 mL/min); no adjustment is needed for mild renal impairment."	( Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Gin, AS; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, PR; Rubinstein, E; Schweizer, F; Sniezek, G; Zelenitsky, S; Zhanel, GG, 2009)	0.35
" No difference in activity was observed between both q8 and q12h dosing regimens of ceftaroline."	( In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Leonard, SN; Rybak, MJ; Vidaillac, C, 2009)	0.35
" Dosage adjustment is required for moderate renal impairment and for patients receiving hemodialysis."	( Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Rybak, MJ; Steed, ME, 2010)	0.36
" aureus isolates of 26% and 33% of the dosing interval, respectively)."	( Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity. Drusano, GL, 2010)	0.36
" Pharmacokinetic and pharmacodynamic target attainment predictions for 600 mg of ceftaroline fosamil every 12 h showed that the mean %T > MICs for which plasma free-drug concentrations exceeded an MIC of 1 and 2 mg/L were 71% and 51% of the dosing interval, respectively."	( Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. Biek, D; Critchley, IA; Riccobene, TA; Thye, DA, 2010)	0.36
" Currently available pharmacokinetic, animal, and clinical studies have found that ceftaroline has reasonable efficacy and tolerability but have also revealed that dosing regimen modifications may be needed in patients with moderate-to-severe renal impairment."	( Ceftaroline: a new broad-spectrum cephalosporin. Brown, J; Lim, L; Sutton, E, 2011)	0.37
" Animals were randomized to the control group (no treatment) (n = 22) or to a group given intravenous (IV) CPT human equivalent (HE) dosage (600 mg/12 h; n = 19) or IV CRO HE dosage (1 g/24 h; n = 19)."	( Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing. Biek, D; Charles, PE; Chavanet, P; Croisier-Bertin, D; Ge, Y; Larribeau, A; Piroth, L, 2011)	0.37
" Two hours after inoculation, a ceftaroline regimen that simulated the percentage of the dosing interval that free-drug concentrations remained above the MIC of the infecting organism (fT>MIC) of humans administered ceftaroline at 600 mg every 12 h (q12h) infused over 1 h was given."	( Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Crandon, JL; Keel, RA; Nicolau, DP, 2011)	0.37
" This combination dosing regimen should allow for optimal bacterial cell kill (highest likelihood of successful clinical outcome) and the suppression of resistance emergence."	( Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Brown, D; Castanheira, M; Critchley, I; Drusano, GL; Grasso, C; Jones, RN; Kulawy, R; Liu, W; Louie, A; Thye, D; Vanscoy, B; Williams, G, 2012)	0.38
" The recommended dosage for patients 18 years and older is 600 mg IV every 12 hours."	( Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Chang, MH; Fung, HB; Poon, H, 2012)	0.38
"5 h after intravenous dosing with a supratherapeutic dose (1,500 mg) of ceftaroline fosamil, 400 mg moxifloxacin (positive control), and placebo."	( Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval. Llorens, L; Rank, D; Rekeda, L; Riccobene, TA, 2013)	0.39
"Pharmacokinetic-pharmacodynamic (PK-PD) analyses for efficacy using phase III trial data from patients treated with a ceftaroline fosamil dosing regimen of 600 mg intravenously (i."	( Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia. Ambrose, PG; Bhavnani, SM; Forrest, A; Friedland, HD; Hammel, JP; Khariton, T; Reynolds, DK; Riccobene, TA; Rubino, CM; Van Wart, SA, 2013)	0.39
") ceftaroline fosamil at 600 mg twice daily (q12h) and simulated patients with renal impairment administered various dosing regimens."	( Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae. Ambrose, PG; Bhavnani, SM; Critchley, IA; Friedland, HD; Khariton, T; Riccobene, TA; Rubino, CM; Van Wart, SA, 2014)	0.4
" Infected rabbits were randomly assigned to no treatment or simulated human-equivalent dosing with ceftaroline fosamil, clindamycin, linezolid, or vancomycin."	( In vivo efficacy of ceftaroline fosamil in a methicillin-resistant panton-valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model. Badiou, C; Biek, D; Charles, PE; Chavanet, P; Croisier-Bertin, D; Da Silva, S; Dumitrescu, O; Guerard, P; Hayez, D; Labrousse, D; Lina, G; Piroth, L; Vandenesch, F, 2014)	0.4
" Ceftaroline pharmacokinetic parameters varied with different degrees of renal impairment, resulting in recommended dosage adjustments for patients with moderate to severe impairment."	( A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis. Jakate, A; Rank, D; Riccobene, T, 2014)	0.4
" Multiple tests revealed the presence of methicillin-resistant Staphylococcus aureus (MRSA) septic arthritis, which was treated with an off-label dosage of ceftaroline (600 mg intravenously every eight hours)."	( A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline. Kwan, BK; Yam, FK, 2014)	0.4
" Using data from the microbiologically evaluable population from two phase 2 and two phase 3 randomized, multicenter, double-blind studies of patients with ABSSSI, an analysis examining the relationship between drug exposure, as measured by the percentage of time during the dosing interval that free-drug steady-state concentrations remain above the MIC (f%T>MIC), and clinical and microbiological responses was undertaken."	( Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections. Ambrose, PG; Bhavnani, SM; Drusano, GL; Forrest, A; Friedland, HD; Hammel, JP; Khariton, T; Reynolds, DK; Riccobene, TA; Rubino, CM; Van Wart, SA, 2015)	0.42
" Three dosing regimens were assessed: 600 mg every 12 h (q12 h) as a 1-h infusion (standard dose) or 600 mg every 8 h (q8 h) as a 2-h infusion in virtual patients with normal renal function; and 400 mg q12 h as a 1-h infusion in patients with moderate renal impairment."	( Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function. Canut, A; Isla, A; Rodríguez-Gascón, A, 2015)	0.42
" No dosage adjustment for ceftaroline appears to be necessary based on TBW alone in adults with comparable eCLCR."	( Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects. Danziger, LH; Justo, JA; Mayer, SM; Novak, RM; Pai, MP; Rodvold, KA; Soriano, MM, 2015)	0.42
" The current dosing regimen of ceftaroline 600 mg intravenously every 12 h appears sufficient to establish pharmacokinetic-pharmacodynamic relationships and achieve optimal clinical efficacy."	( A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline. Ensom, MH; Kiang, TK; Wilby, KJ, 2015)	0.42
"We report four cases of agranulocytosis associated with ceftaroline use, highlighted by prolonged use (more than 14 days) and 8-hour dosing intervals or 12-hour dosing intervals with concomitant clindamycin therapy."	( Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin. Chua, J; Lei, LR; Sakoulas, G; Varada, NL, 2015)	0.42
" The magnitude and timing of peak plasma concentrations of ceftaroline (active metabolite), ceftaroline fosamil (prodrug), and ceftaroline M-1 (inactive metabolite) varied according to the ceftaroline fosamil dosing schedule (q12h or q8h) and infusion duration (60 minutes or 120 minutes), but overall plasma ceftaroline exposures within the respective dosing intervals were broadly similar across cohorts."	( Evaluation of the pharmacokinetics and safety of single and multiple ceftaroline fosamil infusions in healthy Chinese and Western subjects. Edeki, T; Li, H; Li, J; Sunzel, M; Wilson, D; Xu, P; Yang, L, 2015)	0.42
" infusion q12h, administered post-haemodialysis on dialysis days, is an appropriate dosage regimen for ESRD patients."	( An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis. Edeki, T; Learoyd, M; Li, J; Li, Y; Ngo, N; Sunzel, M, 2015)	0.42
" After an interim analysis of the first four patients' pharmacokinetic data, the remaining four patients received a change in dosage of ceftaroline to 600 mg every 8 hours."	( Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis. Anstead, MI; Autry, EB; Burgess, DR; Gardner, BM; Kuhn, RJ; Leung, NR; Rybak, JM, 2016)	0.43
" The PTA for 60% or higher of the dosing interval during which free (unbound) drug concentrations exceed the minimum inhibitory concentration (%fT > MIC) was simulated for various MICs."	( Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis. Anstead, MI; Autry, EB; Burgess, DR; Gardner, BM; Kuhn, RJ; Leung, NR; Rybak, JM, 2016)	0.43
"The pharmacokinetics of ceftaroline is altered in adults with CF, which suggests the need for modified dosing in this patient population to achieve adequate %fT > MIC."	( Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis. Anstead, MI; Autry, EB; Burgess, DR; Gardner, BM; Kuhn, RJ; Leung, NR; Rybak, JM, 2016)	0.43
"Ceftaroline fosamil (CPT-F) is currently approved for use for the treatment of complicated skin and soft tissue infections and community-acquired pneumonia at 600 mg twice daily (q12h), but other dosing regimens are under evaluation."	( Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil. Lackner, E; Lagler, H; Matzneller, P; Österreicher, Z; Wulkersdorfer, B; Zeitlinger, M, 2016)	0.43
" Higher off-label dosing of ceftaroline is often utilized to achieve optimal pharmacokinetic/pharmacodynamic parameters."	( Ceftaroline as Salvage Monotherapy for Persistent MRSA Bacteremia. Burnett, YJ; Echevarria, K; Traugott, KA, 2016)	0.43
" Pediatric dosing differs from adult dosing, but it maintains a similar pharmacokinetic profile and offers similar efficacy in terms of time above the minimum inhibitory concentration as compared to the adult population."	( Current Clinical Trials on the Use of Ceftaroline in the Pediatric Population. Corey, A; So, TY, 2017)	0.46
" The ceftazidime/avibactam efficacy was linked to the proportion of the dosing interval for which the concentration persists above the MIC (fT>MIC), with optimal efficacy at free-drug fT>MIC of 52% (r2 = 0."	( The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent. Chapagain, ML; Cirrincione, KN; Deshpande, D; Gumbo, T; Lee, PS; Pasipanodya, JG; Srivastava, S, 2017)	0.46
"The current CLSI and EUCAST clinical susceptible breakpoint for 600 mg q12h dosing of ceftaroline (active metabolite of ceftaroline fosamil) for Staphylococcus aureus is ≤1 mg/L."	( Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model. Alm, RA; Almutairi, M; Ambler, JE; Chen, A; Lahiri, SD; San Martin, M; Singh, R, 2017)	0.46
"The PK/PD target of ceftaroline was investigated against 12 diverse characterized clinical MRSA isolates with ceftaroline MICs of 2 or 4 mg/L using q8h dosing for 24 h."	( Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model. Alm, RA; Almutairi, M; Ambler, JE; Chen, A; Lahiri, SD; San Martin, M; Singh, R, 2017)	0.46
" HFIM studies with 600 mg q8h dosing demonstrated a sustained long-term bacterial suppression for isolates with ceftaroline MICs of 2 and 4 mg/L."	( Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model. Alm, RA; Almutairi, M; Ambler, JE; Chen, A; Lahiri, SD; San Martin, M; Singh, R, 2017)	0.46
" There are minimal data regarding dosing in the CF population."	( Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. Barsky, EE; Goobie, SM; McAdam, AJ; Pereira, LM; Priebe, GP; Sawicki, GS; Sullivan, KJ; Wong, A, 2018)	0.48
" The dosing regimen studied, which exceeds the recommended dosing in the non-CF population, was adequate to achieve >60% time above the MIC in all patients."	( Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. Barsky, EE; Goobie, SM; McAdam, AJ; Pereira, LM; Priebe, GP; Sawicki, GS; Sullivan, KJ; Wong, A, 2018)	0.48
" A higher mg/kg dose and a more frequent dosing interval for ceftaroline may be needed in PICU patients to provide appropriate pharmacodynamic exposures."	( Ceftaroline for Suspected or Confirmed Invasive Methicillin-Resistant Staphylococcus aureus: A Pharmacokinetic Case Series. Chopra, A; Cies, JJ; Enache, A; Moore, WS, 2018)	0.48
" The β-lactams showed a U-shape dose-response relationship in biofilm prevention."	( In vitro synergism and anti-biofilm activity of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis. Hartung, A; Klinger-Strobel, M; Makarewicz, O; Pletz, MW; Stein, C; Thieme, L, 2018)	0.48
" Food and Drug Administration-recommended doses, and further evaluation is needed before specific drug dosing recommendations can be made for clinical application with extracorporeal membrane oxygenation."	( Oxygenator Impact on Ceftaroline in Extracorporeal Membrane Oxygenation Circuits. Chopra, A; Cies, JJ; Enache, A; Giliam, N; Low, T; Moore, WS, 2018)	0.48
"To describe the pharmacokinetic/pharmacodynamic (PK/PD) modelling and microbiological data that were used to support the recent European approval of ceftaroline fosamil 600 mg q8h by 2 h intravenous (iv) infusion for patients with complicated skin and soft tissue infections (cSSTIs) caused by Staphylococcus aureus with ceftaroline MICs of 2 or 4 mg/L, and the associated EUCAST MIC breakpoint update for q8h dosing (intermediate = 2 mg/L and resistant >2 mg/L)."	( Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections. Das, S; Iaconis, J; Li, J; Melnick, D; Stone, GG; Yan, JL; Zhou, D, 2019)	0.51
" A dosage of 600 mg q8h by 2 h iv infusion is approved in some regions for cSSTI patients with Staphylococcus aureus infection where the ceftaroline MIC is 2 or 4 mg/L."	( Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h. Cheng, K; Hammond, J; Pypstra, R; Yan, JL, 2019)	0.51
" Clinical cure rates in patients with ≥1 systemic inflammatory sign or SIRS were comparable for both ceftaroline fosamil dosage regimens."	( Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials. Corey, GR; Das, S; Dryden, M; Friedland, HD; Gonzalez, J; Iaconis, J; Jandourek, A; Wilcox, MH; Wilson, DJ, 2019)	0.51
" Ceftaroline, when dosed supra-therapeutically for serious infections, may be a cause of antibiotic-associated encephalopathy."	( Ceftaroline-associated Encephalopathy in Patients With Severe Renal Impairment. Chow, S; Johns, ST; Martin, TCS; Mehta, SR, 2020)	0.56
" Single and multiple dosing schemes based on the half-life of ampicillin were applied."	( In vivo synergism of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis assessed in the Galleria mellonella infection model. Hartung, A; Makarewicz, O; Pletz, MW; Thieme, L, 2020)	0.56
"Ampicillin and ceftriaxone exhibited strain-specific synergistic interactions in the larvae under both dosing regimens, while the other two combinations showed additive effects."	( In vivo synergism of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis assessed in the Galleria mellonella infection model. Hartung, A; Makarewicz, O; Pletz, MW; Thieme, L, 2020)	0.56
" This is the first study to develop a scheme for differentiation between additive and synergistic effects in larvae and apply a multiple-antibiotic dosing scheme based on the pharmacokinetics of ampicillin."	( In vivo synergism of ampicillin, gentamicin, ceftaroline and ceftriaxone against Enterococcus faecalis assessed in the Galleria mellonella infection model. Hartung, A; Makarewicz, O; Pletz, MW; Thieme, L, 2020)	0.56
"Currently, no dosing information exists for ceftaroline fosamil in patients undergoing continuous renal replacement therapy (CRRT)."	( Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy. Ali, F; Gopalakrishnan, M; Guo, D; Heavner, M; Jean, W; Kalaria, S; Li, M; Medlin, C; Shu, Y; Williford, S; Yeung, SYA, 2021)	0.62
" Selection of the specific CRRT modality and dosing regimen was based on clinical discretion."	( Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy. Ali, F; Gopalakrishnan, M; Guo, D; Heavner, M; Jean, W; Kalaria, S; Li, M; Medlin, C; Shu, Y; Williford, S; Yeung, SYA, 2021)	0.62
" Ceftaroline fosamil dosing for children (including renal function adjustments) is supported by pharmacokinetic/pharmacodynamic modeling and simulations in appropriate age groups, and includes the option of 5- to 60-min intravenous infusions for standard doses, and a high dose for cSSTI patients with MRSA isolates, with a ceftaroline minimum inhibitory concentration of 2-4 mg/L."	( Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia. Carrothers, TJ; Esposito, S; Kantecki, M; Riccobene, T; Stone, GG, 2021)	0.62
" The objective of the study was to explore the impact of ARC on ceftaroline pharmacokinetics and evaluate whether the currently recommended dosing regimen (600 mg every 12 h) is appropriate to treat VAP in ICU patients."	( Population pharmacokinetic/pharmacodynamic study suggests continuous infusion of ceftaroline daily dose in ventilated critical care patients with early-onset pneumonia and augmented renal clearance. Ashenoune, K; Boisson, M; Chauzy, A; Couet, W; Dahyot-Fizelier, C; Ferrandière, M; Gregoire, N; Lasocki, S; Marchand, S; Mimoz, O; Seguin, P, 2022)	0.72
" Monte Carlo simulations were conducted to determine the PTA and the cumulative fraction of response (CFR) against Streptococcus pneumoniae and MRSA for five dosing regimens."	( Population pharmacokinetic/pharmacodynamic study suggests continuous infusion of ceftaroline daily dose in ventilated critical care patients with early-onset pneumonia and augmented renal clearance. Ashenoune, K; Boisson, M; Chauzy, A; Couet, W; Dahyot-Fizelier, C; Ferrandière, M; Gregoire, N; Lasocki, S; Marchand, S; Mimoz, O; Seguin, P, 2022)	0.72
" Ampicillin's inconvenient dosing schedule, drug instability, allergy potential, along with ceftriaxone's high risk for Clostridioides difficile infection and its promotion of vancomycin-resistant enterococci (VRE), led our team to explore alternative options."	( Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an Cusumano, JA; Daffinee, KE; Desbonnet, C; García-Solache, M; LaPlante, KL; Piehl, EC; Rice, LB, 2022)	0.72
" This study aimed to evaluate dosing regimens for coadministration of daptomycin and ceftaroline in special populations including paediatrics, renally impaired (RI), obese and geriatrics that generate sufficient coverage against daptomycin-resistant MRSA."	( Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations. Annaert, P; Martins, FS; Martins, JES; Severino, P; Sy, SKB, 2023)	0.91
"The adult dosing regimens of 6 mg/kg every (q)24h or q48h daptomycin and 300-600 mg q12h ceftaroline fosamil by RI categories achieved ≥90% joint PTA when the minimum inhibitory concentrations in the combination are at or below 1 and 4 μg/mL against MRSA."	( Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations. Annaert, P; Martins, FS; Martins, JES; Severino, P; Sy, SKB, 2023)	0.91
"Our work illustrates how physiologically based pharmacokinetic modelling can inform appropriate dosing of adult and paediatric patients and thereby enable prediction of target attainment in the patients during multitherapies."	( Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations. Annaert, P; Martins, FS; Martins, JES; Severino, P; Sy, SKB, 2023)	0.91
" For β-lactam antibiotics, such as ceftaroline, prolonged infusions and therapeutic drug monitoring (TDM) are used for dosage optimization based on their pharmacokinetics/pharmacodynamics (PK/PD)."	( Real-world experience of therapeutic drug monitoring and PK/PD achievement of ceftaroline administered by different infusion regimens in patients with confirmed infections caused by Gram-positive bacteria. Benítez-Cano, A; De-Antonio, M; Fresán, D; Grau, S; Horcajada, JP; Luque, S; Montero, MM; Roberts, JA; Sorlí, L; Vega, V, 2023)	0.91

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

Role	Description
antibacterial drug	A drug used to treat or prevent bacterial infections.
antimicrobial agent	A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
prodrug	A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

Class	Description
iminium betaine
cephalosporin	A class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
1,3-thiazoles
oxime O-ether	O-organyl oximes R2C=NOR' (R' =/= H).
thiadiazoles
organic phosphoramidate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (644)

Assay ID	Title	Year	Journal	Article
AID545843	Antimicrobial activity against ESBL-negative Klebsiella pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID573334	Antibacterial activity against ceftazidime-susceptible Enterobacteriaceae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID522131	Antimicrobial activity against Bacteroides fragilis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID534784	Bactericidal activity against community-acquired methicillin-resistant Staphylococcus aureus expressing SCCmec type 4 element assessed as antibiotic concentration that reduced the number of viable cells by =>99.9% by colony count method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID560073	Antimicrobial activity against Enterobacter cloacae isolate 4073 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID368284	Cmax in rabbit plasma at 58 mg/kg after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID368289	Bactericidal activity against vancomycin-intermediate Staphylococcus aureus in rabbit endocarditis model assessed per gram of aortic vegetation at 58 mg/kg infused every 12 hrs for 4 days measured after 48 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID524050	Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP2 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID543283	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 pbp2x, pbp1a, pbp2b and Streptococcus pneumoniae 3191 murM genes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID522144	Antimicrobial activity against Prevotella bergensis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID523238	Toxicity against healthy human assessed as effect on ECG parameters at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 9	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID573128	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID546062	Antimicrobial activity against beta-lactamase-negative Haemophilus influenzae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID573141	Antibacterial activity against erythromycin-nonsusceptible Streptococcus agalactiae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID573382	Antibacterial activity against beta lactamase-positive Haemophilus influenzae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID534785	Bactericidal activity against community-acquired methicillin-resistant Staphylococcus aureus expressing SCCmec type 2 element assessed as antibiotic concentration that reduced the number of viable cells by =>99.9% by colony count method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID564727	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 609 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524213	Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP2A by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID573355	Antibacterial activity against ceftazidime-nonsusceptible Escherichia coli by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID560093	Bactericidal activity against Escherichia coli isolate 5401 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID545828	Antimicrobial activity against vancomycin-susceptible Enterococcus faecium by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID524067	Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP4 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID546064	Antimicrobial activity against beta-lactamase-negative ampicillin resistant Haemophilus influenzae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID574952	Antimicrobial activity against Streptococcus pneumoniae serotype 11A by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID545824	Antimicrobial activity against methicillin-susceptible coagulase-negative Staphylococcus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID522193	Antimicrobial activity against Lactobacillus rhamnosus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID573346	Antibacterial activity against ceftazidime-susceptible Enterobacter cloacae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID560207	Volume of distribution in patient with complicated skin and skin structure infection	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID523236	Antibacterial activity against Clostridium in healthy human intestine assessed as decrease in bacterial count at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 7	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID560067	Antimicrobial activity against Escherichia coli isolate 5401 by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID564711	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 266 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524069	Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP4 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID522205	Antimicrobial activity against Clostridium cadaveris under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID564913	Antimicrobial activity against methicillin-resistant, vancomycin-hetroresistant Staphylococcus aureus 618 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID545827	Antimicrobial activity against Enterococcus faecium by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID573149	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID546066	fT>MIC Staphylococcus aureus infected mouse model for 1-log kill	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID560072	Antimicrobial activity against Klebsiella pneumoniae isolate 5436 by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID523362	Toxicity against healthy human assessed as occurrence of urinary infection at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 9	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID522170	Antimicrobial activity against Anaerococcus sp. under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID368295	%T>MIC in methicillin-resistant Staphylococcus aureus SA2 in mouse thigh/lung infection model	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID565150	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae s502 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID546061	Antimicrobial activity against Moraxella catarrhalis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID522190	Antimicrobial activity against Slackia exigua under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522199	Antimicrobial activity against Clostridium bolteae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522179	Antimicrobial activity against Actinomyces turicensis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID496293	AUC (0 to infinity) in iv dosed monkey administered as single bolus dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID522132	Antimicrobial activity against Bacteroides thetaiotaomicron under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522207	Antimicrobial activity against Clostridium difficile under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID534795	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID565130	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 10 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID573134	Antibacterial activity against erythromycin-nonsusceptible Streptococcus pyogenes by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID560080	Antimicrobial activity against Pseudomonas aeruginosa isolate 1037 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID546059	Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID535013	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID524219	Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP3 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID560062	Antimicrobial activity against ESBL-producing Klebsiella pneumoniae by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID564942	Antimicrobial activity against methicillin-resistant, vancomycin-susceptible Staphylococcus aureus vs1 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560332	Bactericidal activity against Pseudomonas aeruginosa isolate 956 at 1/4 times MIC after 8 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID573364	Antibacterial activity against ceftazidime-susceptible Morganella morganii by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID522186	Antimicrobial activity against Eubacterium cylindroides under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID546060	Antimicrobial activity against Stenotrophomonas maltophilia by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID524046	Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP1 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID573125	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID522206	Antimicrobial activity against Clostridium celerecrescens under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID543280	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 pbp2x, pbp2b and Streptococcus pneumoniae 3191 pbp1a genes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID496280	Tmax in im dosed rabbit administered as single dose by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID545838	Antimicrobial activity against Streptococcus viridans group clinical isolate by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID545832	Antimicrobial activity against levofloxacin-resistant Streptococcus pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID523248	Antibacterial activity against Clostridium perfringens by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID545846	Antimicrobial activity against Proteus mirabilis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID545841	Antimicrobial activity against ESBL-negative Escherichia coli by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID535256	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-4 expressing SCCmec type 4 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID560105	Bactericidal activity against Pseudomonas aeruginosa isolate 1019 at 1/4 times MIC after 2 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID560081	Antimicrobial activity against Pseudomonas aeruginosa isolate 796 by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID560201	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID560060	Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID560083	Antimicrobial activity against Pseudomonas aeruginosa isolate 1019 by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID523244	Antibacterial activity against Bacteroides fragilis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID522180	Antimicrobial activity against Propionibacterium acnes under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID535257	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-5 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID560063	Antimicrobial activity against Enterobacter cloacae by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID524061	Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP3 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID524058	Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP2a by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID519146	Antimicrobial activity against Serratia marcescens by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID560070	Antimicrobial activity against Klebsiella pneumoniae isolate 5436 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID564937	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae ATCC 49617 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID522175	Antimicrobial activity against Actinomyces israelii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID523232	Antibacterial activity against Escherichia coli in healthy human intestine assessed as decrease in bacterial count at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 14	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID574951	Antimicrobial activity against Streptococcus pneumoniae serotype 7F by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID522157	Antimicrobial activity against Fusobacterium varium under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID533874	Antibacterial activity against penicillin-nonsusceptible Streptococcus pneumoniae isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID535016	Bactericidal activity against daptomycin-nonsusceptible Staphylococcus aureus assessed as antibiotic concentration that reduced the number of viable cells by =>99.9% by colony count method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID519138	Antimicrobial activity against community-acquired methicillin resistant Staphylococcus aureus expressing PVL and mec type IV gene by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID522182	Antimicrobial activity against Eggerthella lenta under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522142	Antimicrobial activity against Prevotella melaninogenica under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID573379	Antibacterial activity against beta lactamase-negative Haemophilus influenzae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID546065	fT>MIC Streptococcus pneumoniae infected mouse model for 1-log kill	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID535006	Bactericidal activity against vancomycin-intermediate Staphylococcus aureus assessed as antibiotic concentration that reduced the number of viable cells by =>99.9% by colony count method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID496275	Terminal half life in im dosed rat administered as single dose by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID368305	Antibacterial activity against Neisseria meningitidis	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID560076	Antimicrobial activity against Enterobacter cloacae isolate 5420 by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID545833	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID564911	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus sox1 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560340	Bactericidal activity against Escherichia coli isolate 5411 at 1/4 times MIC after 8 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID565159	Antimicrobial activity against methicillin-resistant, vancomycin-intermediate Staphylococcus aureus 510 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID545837	Antimicrobial activity against macrolide-susceptible Streptococcus pyogenes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID545836	Antimicrobial activity against macrolide-resistant Streptococcus pyogenes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID573343	Antibacterial activity against ceftazidime-nonsusceptible Citrobacter freundii by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID560089	Bactericidal activity against Enterobacter cloacae isolate 4073 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID524066	Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP3 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID560059	Antimicrobial activity against AmpC-depressed Enterobacter cloacae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID546058	Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID573352	Antibacterial activity against ceftazidime-susceptible Escherichia coli by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID573155	Antibacterial activity against vancomycin-resistant Enterococcus faecium by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID564930	Antimicrobial activity against methicillin-resistant, vancomycin-intermediate Staphylococcus aureus 510 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID522169	Antimicrobial activity against Anaerococcus vaginalis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID560082	Antimicrobial activity against Pseudomonas aeruginosa isolate 956 by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID560079	Antimicrobial activity against Pseudomonas aeruginosa isolate 1019 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID535025	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-24 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID543275	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2x and pbp1a genes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID565148	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 266 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524068	Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP4 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID522212	Antimicrobial activity against Clostridium sphenoides under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID573358	Antibacterial activity against ceftazidime-susceptible Klebsiella pneumoniae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524033	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae 1394 by macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID560077	Antimicrobial activity against Pseudomonas aeruginosa isolate 796 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID545823	Antimicrobial activity against methicillin-resistant coagulase-negative Staphylococcus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID545840	Antimicrobial activity against ESBL-negative Enterobacter cloacae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID533878	Antibacterial activity against amoxicillin-resistant Streptococcus pneumoniae isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID560349	Bactericidal activity against Escherichia coli isolate 5401 at 1/4 times MIC after 24 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID522148	Antimicrobial activity against Prevotella loescheii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID565161	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 20 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID573122	Antibacterial activity against coagulase-negative and oxacillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID564919	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 266 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560106	Bactericidal activity against Pseudomonas aeruginosa isolate 1037 at 1/4 times MIC after 2 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID573340	Antibacterial activity against ceftazidime-susceptible Citrobacter freundii by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524203	Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP1B by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID524221	Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP3 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID368304	Antibacterial activity against Moraxella catarrhalis	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID524064	Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP3 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID535273	Antimicrobial activity against methicillin-resistant Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID560064	Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID523246	Antibacterial activity against Propionibacterium by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID573367	Antibacterial activity against ceftazidime-susceptible Proteus mirabilis by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID519141	Antimicrobial activity against Citrobacter freundii by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID545825	Antimicrobial activity against Enterococcus faecalis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID564927	Antimicrobial activity against methicillin-resistant, vancomycin-susceptible Staphylococcus aureus vs1 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID573116	Antibacterial activity against methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID522155	Antimicrobial activity against Fusobacterium necrophorum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID546054	Antimicrobial activity against Serratia marcescens by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID564708	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 10 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID522188	Antimicrobial activity against Eubacterium saburreum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID535008	Antimicrobial activity against daptomycin-nonsusceptible Staphylococcus aureus by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID522147	Antimicrobial activity against Prevotella disiens under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID546052	Antimicrobial activity against Proteus stuartii by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID573337	Antibacterial activity against ceftazidime-nonsusceptible Enterobacteriaceae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID573370	Antibacterial activity against ceftazidime-susceptible Serratia marcescens by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID573152	Antibacterial activity against vancomycin-resistant Enterococcus faecalis by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID522154	Antimicrobial activity against Fusobacterium nucleatum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID560326	Bactericidal activity against Enterobacter cloacae isolate 5420 at 1/4 times MIC after 4 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID573385	Antibacterial activity against beta lactamase-positive Moraxella catarrhalis by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID368296	%T>MIC in vancomycin-intermediate Staphylococcus aureus in mouse thigh/lung infection model	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID564699	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae ATCC 49617 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564896	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus sox1 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560110	Bactericidal activity against Klebsiella pneumoniae isolate 5436 at 1/4 times MIC after 2 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID522151	Antimicrobial activity against Prevotella tannerae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522138	Antimicrobial activity against Bacteroides uniformis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID564722	Antimicrobial activity against methicillin-resistant, vancomycin-intermediate Staphylococcus aureus 510 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID565133	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 266 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID368297	Half life in rabbit	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID564700	Antimicrobial activity against Penicillin-intermediate Streptococcus pneumoniae s1234 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID522172	Antimicrobial activity against Gemella sanguinis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID564900	Antimicrobial activity against methicillin-resistant, vancomycin-intermediate Staphylococcus aureus 510 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564912	Antimicrobial activity against methicillin-resistant, vancomycin-susceptible Staphylococcus aureus vs1 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564922	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae ATCC 49617 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID368275	Antibacterial activity against Citrobacter freundii	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID565165	Antimicrobial activity against Staphylococcus aureus ATCC 29213 infected in neutropenic ICR mouse assessed as post antibiotic effect at 1.56 to 100 mg/kg, sc administered 14 hrs post infection	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID543269	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 pbp2x gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID523237	Antibacterial activity against Bacteroides sp. in healthy human intestine assessed as decrease in bacterial count at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 21	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID545826	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID560206	Cmax in healthy human at 600 mg/kg, iv administered as 1 hr infusion every 12 hrs for 14 days measured after last dose	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID545834	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID565136	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae ATCC 49617 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID522152	Antimicrobial activity against Porphyromonas asaccharolyticus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522176	Antimicrobial activity against Actinomyces meyeri under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID545830	Antimicrobial activity against Listeria monocytogenes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID573361	Antibacterial activity against ceftazidime-nonsusceptible Klebsiella pneumoniae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID545829	Antimicrobial activity against Corynebacterium jeikeium by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID573119	Antibacterial activity against coagulase-negative and oxacillin-susceptible Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1489545	Antibiofilm activity against methicillin-resistant Staphylococcus aureus LAC established catheter-associated biofilm model at 20 times MIC after 72 hrs relative to control	2017	Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23	Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin.
AID565135	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae s502 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID573138	Antibacterial activity against erythromycin-susceptible Streptococcus agalactiae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID573391	Antibacterial activity against ceftazidime-susceptible Providencia sp. by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID573373	Antibacterial activity against multidrug-resistant Acinetobacter by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID496296	Tmax in iv dosed monkey administered as single bolus dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID496281	AUC (0 to infinity) in im dosed monkey administered as single dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID565127	Antimicrobial activity against methicillin-resistant, vancomycin-hetroresistant Staphylococcus aureus 618 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560099	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase inhibitor CTX-M by agar diffusion method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID573143	Antibacterial activity against penicillin-susceptible Streptococcus viridans by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID546056	Antimicrobial activity against Salmonella spp. by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID560107	Bactericidal activity against Enterobacter cloacae isolate 4073 at 1/4 times MIC after 2 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID573113	Antibacterial activity against methicillin-susceptible Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID522165	Antimicrobial activity against Peptostreptococcus stomatis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID543277	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2x and pbp2b genes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID522173	Antimicrobial activity against Peptoniphilus harei under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID565131	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 20 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID522196	Antimicrobial activity against Clostridium inoculum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID574954	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19A by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID560325	Bactericidal activity against Enterobacter cloacae isolate 4073 at 1/4 times MIC after 4 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID524204	Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP1B by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID543273	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2x gene by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID564725	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis ATCC 29212 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID565141	Antimicrobial activity against methicillin-resistant, vancomycin-susceptible Staphylococcus aureus vs1 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID522159	Antimicrobial activity against Anaerococcus prevotii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID543271	Antimicrobial activity against Streptococcus pneumoniae 3191 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID565155	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus sox1 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID546057	Antimicrobial activity against Burkholderia cepacia by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID565146	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 20 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524201	Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP1A by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID522214	Antimicrobial activity against Clostridium symbiosum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID523233	Antibacterial activity against Enterobacteriaceae in healthy human intestine assessed as decrease in bacterial count at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 14	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID496294	Cmax in iv dosed monkey administered as single bolus dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID522168	Antimicrobial activity against Anaerococcus octavius under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID523360	Antibacterial activity against Clostridium difficile by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID564719	Antimicrobial activity against methicillin-resistant, vancomycin-susceptible Staphylococcus aureus vs1 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560195	Inhibition of methicillin-resistant Staphylococcus aureus PBP 2a	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID496300	%T>MIC in rabbit endocarditis model at 20 mg/kg, im administered as single dose measured after 8 hrs	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID496289	AUC (0 to infinity) in iv dosed rabbit administered as single bolus dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID543274	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2b, pbp1a and murM genes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID574950	Antimicrobial activity against Streptococcus pneumoniae serotype 35B by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID534782	Antimicrobial activity against community-acquired methicillin-resistant Staphylococcus aureus expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID545847	Antimicrobial activity against Proteus rettgeri by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID522191	Antimicrobial activity against Solobacterium moorei under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522209	Antimicrobial activity against Clostridium hylemonae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID524206	Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP1B by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID560066	Antimicrobial activity against Escherichia coli isolate 5411 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID574949	Antimicrobial activity against Streptococcus pneumoniae serotype 3 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID522203	Antimicrobial activity against Clostridium bifermentans under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID564902	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 20 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID496279	Terminal half life in im dosed rabbit administered as single dose by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID535262	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-10 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID560090	Bactericidal activity against Enterobacter cloacae isolate 5420 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID560342	Bactericidal activity against Pseudomonas aeruginosa isolate 956 at 1/4 times MIC after 24 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID565129	Antimicrobial activity against methicillin-resistant, vancomycin-intermediate Staphylococcus aureus 510 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560199	Binding affinity to methicillin-susceptible Staphylococcus aureus PBP 3	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID522204	Antimicrobial activity against Clostridium butyricum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522183	Antimicrobial activity against Atopobium parvulum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID565145	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 10 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID522178	Antimicrobial activity against Actinomyces odontolyticus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID560333	Bactericidal activity against Pseudomonas aeruginosa isolate 1019 at 1/4 times MIC after 8 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID368277	Bactericidal activity against vancomycin-intermediate Staphylococcus aureus by microdilution technique	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID534084	Antibacterial activity against erythromycin-resistant Streptococcus pneumoniae isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID524222	Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP3 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID522208	Antimicrobial activity against Clostridium glycolicum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID545820	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID565134	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 609 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560204	Antimicrobial activity against community-acquired Staphylococcus aureus	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID560057	Antimicrobial activity against ESBL-producing Escherichia coli by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID560335	Bactericidal activity against Enterobacter cloacae isolate 4073 at 1/4 times MIC after 8 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID560338	Bactericidal activity against Klebsiella pneumoniae isolate 5436 at 1/4 times MIC after 8 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID534793	Bactericidal activity against community-acquired methicillin-resistant Staphylococcus aureus assessed as antibiotic concentration that reduced the number of viable cells by =>99.9% by colony count method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID564730	Antimicrobial activity against Penicillin-intermediate Streptococcus pneumoniae s1234 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564712	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 609 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560329	Bactericidal activity against Escherichia coli isolate 5401 at 1/4 times MIC after 4 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID524035	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae 3413 by macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID522150	Antimicrobial activity against Prevotella oris under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID535037	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-404 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID535021	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-18 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID564703	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus sox1 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524055	Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP2 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID545831	Antimicrobial activity against Streptococcus agalactiae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID524202	Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP1A by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID524053	Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP2 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID368299	Protein binding in rabbit plasma	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID560097	Antimicrobial activity against Escherichia coli expressing beta-lactamase inhibitor TEM-2 by agar diffusion method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID573146	Antibacterial activity against penicillin-nonsusceptible Streptococcus viridans by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID564928	Antimicrobial activity against methicillin-resistant, vancomycin-hetroresistant Staphylococcus aureus 618 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID535259	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-7 expressing SCCmec element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID564710	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis ATCC 29212 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID496285	AUC (0 to infinity) in iv dosed rat administered as single bolus dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID522137	Antimicrobial activity against Bacteroides ovatus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID560347	Bactericidal activity against Klebsiella pneumoniae isolate 5427 at 1/4 times MIC after 24 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID574953	Antimicrobial activity against Streptococcus pneumoniae serotype 6C by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID522146	Antimicrobial activity against Prevotella denticola under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID545844	Antimicrobial activity against ESBL-positive Klebsiella pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID522195	Antimicrobial activity against Clostridium ramosum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID368286	Half life in rabbit plasma at 58 mg/kg after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID368294	%T>MIC in methicillin-resistant Staphylococcus aureus in mouse thigh/lung infection model	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID522181	Antimicrobial activity against Propionibacterium avidum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID560075	Antimicrobial activity against Enterobacter cloacae isolate 4073 by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID496286	Cmax in iv dosed rat administered as single bolus dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID545819	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID560088	Bactericidal activity against Pseudomonas aeruginosa isolate 1037 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID522153	Antimicrobial activity against Porphyromonas somerae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID524052	Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP2 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID560102	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase inhibitor SHV-1 by agar diffusion method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID565164	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 609 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564904	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 266 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID546053	Antimicrobial activity against Proteus vulgaris by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID534786	Antimicrobial activity against community-acquired methicillin-resistant Staphylococcus aureus by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID546055	Antimicrobial activity against Shigella spp. by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID560101	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase inhibitor TEM-2 by agar diffusion method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID524060	Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP2a by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID564915	Antimicrobial activity against methicillin-resistant, vancomycin-intermediate Staphylococcus aureus 510 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID534082	Antibacterial activity against cefotaxime-resistant Streptococcus pneumoniae isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID522143	Antimicrobial activity against Prevotella intermedia under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID543282	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 pbp2x, pbp1a, pbp2b genes and Streptococcus pneumoniae 3191 genomic DNA by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID496290	Cmax in iv dosed rabbit administered as single bolus dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID573131	Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID560345	Bactericidal activity against Enterobacter cloacae isolate 4073 at 1/4 times MIC after 24 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID565137	Antimicrobial activity against Penicillin-intermediate Streptococcus pneumoniae s1234 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564931	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 10 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID522210	Antimicrobial activity against Clostridium paraputrificum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID524044	Binding affinity to methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 PBP1 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID545839	Antimicrobial activity against ESBL-negative Enterobacter aerogenes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID563497	Antibacterial activity against vancomycin-resistant Enterococcus faecalis EF NJ1 infected in New Zealand White rabbit assessed as log reduction of bacterial count in aortic valve vegetations at 10 mg/kg, iv administered every 12 hrs for 4 days	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and van
AID560324	Bactericidal activity against Pseudomonas aeruginosa isolate 1037 at 1/4 times MIC after 4 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID535018	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-3 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID535031	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-74 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID523225	Plasma concentration in healthy human at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 2	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID545821	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID574955	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 19F by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID534088	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID560068	Antimicrobial activity against Escherichia coli isolate 5411 by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID524062	Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP3 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID522160	Antimicrobial activity against Anaerococcus tetradius under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522202	Antimicrobial activity against Clostridium baratii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522164	Antimicrobial activity against Peptostreptococcus anaerobius under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID524051	Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP2 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID522375	Antimicrobial activity against Eubacterium limosum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522211	Antimicrobial activity against Clostridium sordellii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID560069	Antimicrobial activity against Klebsiella pneumoniae isolate 5427 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID496288	Tmax in iv dosed rat administered as single bolus dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID533876	Antibacterial activity against amoxicillin-intermediate Streptococcus pneumoniae isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID545845	Antimicrobial activity against Morganella morganii by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID524063	Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP3 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID522213	Antimicrobial activity against Clostridium subterminale under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID496306	Antibacterial activity against Staphylococcus infected in human	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID1308268	Antibacterial activity against Staphylococcus aureus COL expressing pbp2a antisense plasmid assessed as increase in zone of inhibition after 18 to 20 hrs in presence of xylose	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials.
AID535023	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-22 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID564925	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus ATCC 29213 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID543270	Antimicrobial activity against Streptococcus pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID496298	%T>MIC in Staphylococcus aureus-infected neutropenic mouse model	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID519143	Antimicrobial activity against Klebsiella pneumoniae by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID565166	Antimicrobial activity against Streptococcus pneumoniae ATCC 10813 infected in neutropenic ICR mouse assessed as post antibiotic effect at 1.56 to 100 mg/kg, sc administered 14 hrs post infection	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560214	Half life in serum of patient with complicated skin and skin structure infection	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID564906	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae s502 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID368285	AUC in rabbit plasma at 58 mg/kg after 12 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID560321	Bactericidal activity against Pseudomonas aeruginosa isolate 796 at 1/4 times MIC after 4 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID496301	%T>MIC in rabbit endocarditis model at 20 mg/kg, im administered as single dose measured after 12 hrs	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID574948	Antimicrobial activity against Streptococcus pneumoniae serotype 19A by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID368298	Protein binding in human plasma	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID560203	Antimicrobial activity against daptomycin-nonsusceptible Staphylococcus aureus	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID522177	Antimicrobial activity against Actinomyces neuii subsp. anitratus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID523242	Antibacterial activity against Enterococcus faecalis ATCC 29212 at =< 4 mg/L after 48 hrs by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID560065	Antimicrobial activity against Escherichia coli isolate 5401 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID522149	Antimicrobial activity against Prevotella nanceiensis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID524049	Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP1 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID560348	Bactericidal activity against Klebsiella pneumoniae isolate 5436 at 1/4 times MIC after 24 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID573388	Antibacterial activity against Pasteurella multocida by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID496303	Antibacterial activity against Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID496291	Terminal half life in iv dosed rabbit administered as single bolus dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID560198	Binding affinity to methicillin-susceptible Staphylococcus aureus PBP 2	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID524199	Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP1A by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID534791	Bactericidal activity against vancomycin-resistant Staphylococcus aureus assessed as antibiotic concentration that reduced the number of viable cells by =>99.9% by colony count method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID522166	Antimicrobial activity against Anaerococcus lactolyticus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID546063	Antimicrobial activity against beta-lactamase-positive Haemophilus influenzae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID565160	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 10 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524059	Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP2a by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID545835	Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID560078	Antimicrobial activity against Pseudomonas aeruginosa isolate 956 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID560197	Binding affinity to methicillin-susceptible Staphylococcus aureus PBP 1	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID522185	Antimicrobial activity against Eubacterium contortum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522133	Antimicrobial activity against Bacteroides fragilis spp. under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID535020	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-17 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID522136	Antimicrobial activity against Bacteroides merdae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID560200	Binding affinity to methicillin-susceptible Staphylococcus aureus PBP 4	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID522162	Antimicrobial activity against Parvimonas micra under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID524217	Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP2B by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID523240	Antibacterial activity against Clostridium difficile ATCC 700057 after 48 hrs by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID560058	Antimicrobial activity against ESBL-producing Klebsiella pneumoniae by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID368291	Bactericidal activity against vancomycin-intermediate Staphylococcus aureus in rabbit endocarditis model assessed as growth inhibition at 58 mg/kg infused every 12 hrs for 4 days measured after 48 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID564701	Antimicrobial activity against Penicillin-, erythromycin-resistant Streptococcus pneumoniae 37 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID368276	Bactericidal activity against methicillin-resistant Staphylococcus aureus SA2 by microdilution technique	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID522158	Antimicrobial activity against Veillonella spp. under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522194	Antimicrobial activity against Clostridium perfringens under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID560086	Bactericidal activity against Pseudomonas aeruginosa isolate 956 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID522215	Antimicrobial activity against Clostridium tertium under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522141	Antimicrobial activity against Prevotella buccae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID524212	Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP2A by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID496278	Cmax in im dosed rabbit administered as single dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID533880	Antibacterial activity against cefotaxime-intermediate Streptococcus pneumoniae isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID523235	Antibacterial activity against Lactobacillus in healthy human intestine assessed as log reduction in bacterial count per gram of feces at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 7	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID564929	Antimicrobial activity against methicillin-resistant, vancomycin-resistant Staphylococcus aureus 770 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560100	Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase inhibitor TEM-1 by agar diffusion method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID522171	Antimicrobial activity against Gemella morbillorum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID565138	Antimicrobial activity against Penicillin-, erythromycin-resistant Streptococcus pneumoniae 37 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID368290	Bactericidal activity against methicillin-resistant Staphylococcus aureus SA2 in rabbit endocarditis model assessed as growth inhibition at 58 mg/kg infused every 12 hrs for 4 days measured after 48 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID564898	Antimicrobial activity against methicillin-resistant, vancomycin-hetroresistant Staphylococcus aureus 618 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID522134	Antimicrobial activity against Bacteroides caccae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522167	Antimicrobial activity against Anaerococcus murdochii under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID574956	Antimicrobial activity against multiple drug resistant Streptococcus pneumoniae serotype 6B by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
AID524039	Antibacterial activity against methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 by macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID535032	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-76 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID522198	Antimicrobial activity against Clostridium aldenense under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID560112	Bactericidal activity against Escherichia coli isolate 5411 at 1/4 times MIC after 2 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID565140	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus sox1 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID522140	Antimicrobial activity against Prevotella bivia under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522184	Antimicrobial activity against Colinsella aerofaciens under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522135	Antimicrobial activity against Bacteroides distasonis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID496295	Terminal half life in iv dosed monkey administered as single bolus dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID535035	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-402 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID573376	Antibacterial activity against imipenem-susceptible Acinetobacter by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID560328	Bactericidal activity against Klebsiella pneumoniae isolate 5436 at 1/4 times MIC after 4 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID564901	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 10 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID534086	Antibacterial activity against levofloxacin-resistant Streptococcus pneumoniae isolate by agar dilution method	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.
AID524048	Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP1 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID564924	Antimicrobial activity against Penicillin-, erythromycin-resistant Streptococcus pneumoniae 37 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID522200	Antimicrobial activity against Clostridium citroniae under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID564718	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus sox1 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID565151	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae ATCC 49617 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID522161	Antimicrobial activity against Finegoldia magna under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID565128	Antimicrobial activity against methicillin-resistant, vancomycin-resistant Staphylococcus aureus 770 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524036	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae 2527 by macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID522139	Antimicrobial activity against Bacteroides vulgatus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID560084	Antimicrobial activity against Pseudomonas aeruginosa isolate 1037 by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID563320	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis EF 12704 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and van
AID524040	Antibacterial activity against methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 by macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID560327	Bactericidal activity against Klebsiella pneumoniae isolate 5427 at 1/4 times MIC after 4 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID543262	Antimicrobial activity against Streptococcus pneumoniae R6 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID564941	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus sox1 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID496283	Terminal half life im dosed monkey administered as single dose by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID1308270	Antibacterial activity against Staphylococcus aureus COL expressing pbp3 antisense plasmid assessed as increase in zone of inhibition after 18 to 20 hrs in presence of xylose	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials.
AID565132	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis ATCC 29212 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID545842	Antimicrobial activity against ESBL-positive Escherichia coli by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID522189	Antimicrobial activity against Mogibacterium timidum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID543279	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 pbp2x, pbp1a and pbp2b genes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID564921	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae s502 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID522163	Antimicrobial activity against Peptoniphilus asaccharolyticus under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522197	Antimicrobial activity against Clostridium clostridioforme under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID573349	Antibacterial activity against ceftazidime-nonsusceptible Enterobacter cloacae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524043	Antibacterial activity against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 by macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID564709	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 20 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID523239	Antibacterial activity against Bacteroides fragilis ATCC 25285 after 48 hrs by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID564726	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 266 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID523359	Antibacterial activity against Clostridium septicum by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID535253	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-1 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID563322	Antibacterial activity against vancomycin-resistant Enterococcus faecalis EF NJ1 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and van
AID560071	Antimicrobial activity against Klebsiella pneumoniae isolate 5427 by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID522201	Antimicrobial activity against Clostridium hathewayi under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID522174	Antimicrobial activity against Peptoniphilus lacrimalis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID524218	Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP2B by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID564704	Antimicrobial activity against methicillin-resistant, vancomycin-susceptible Staphylococcus aureus vs1 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560196	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 29213 by CLSI method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID560092	Bactericidal activity against Klebsiella pneumoniae isolate 5436 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID523231	Antibacterial activity against Escherichia coli in healthy human intestine assessed as log reduction in bacterial count per gram of feces at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 9	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID524032	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae 2688 by macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID565142	Antimicrobial activity against methicillin-resistant, vancomycin-hetroresistant Staphylococcus aureus 618 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564731	Antimicrobial activity against Penicillin-, erythromycin-resistant Streptococcus pneumoniae 37 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564940	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus ATCC 29213 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524205	Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP1B by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID564721	Antimicrobial activity against methicillin-resistant, vancomycin-resistant Staphylococcus aureus 770 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564897	Antimicrobial activity against methicillin-resistant, vancomycin-susceptible Staphylococcus aureus vs1 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560087	Bactericidal activity against Pseudomonas aeruginosa isolate 1019 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID496302	Antibacterial activity against Staphylococcus	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID535255	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-3 expressing SCCmec type 4 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID564702	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus ATCC 29213 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID368303	Antibacterial activity against Haemophilus influenzae	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID564729	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae ATCC 49617 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560061	Antimicrobial activity against ESBL-producing Escherichia coli by broth microdilution method in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID564920	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 609 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID535033	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-118 expressing SCCmec type 1 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID564717	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus ATCC 29213 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560346	Bactericidal activity against Enterobacter cloacae isolate 5420 at 1/4 times MIC after 24 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID560350	Bactericidal activity against Escherichia coli isolate 5411 at 1/4 times MIC after 24 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID524198	Binding affinity to against methicillin-, daptomycin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 25 PBP4 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID564899	Antimicrobial activity against methicillin-resistant, vancomycin-resistant Staphylococcus aureus 770 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524071	Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP4 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID535030	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-73 expressing SCCmec type 4d element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID565152	Antimicrobial activity against Penicillin-intermediate Streptococcus pneumoniae s1234 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560344	Bactericidal activity against Pseudomonas aeruginosa isolate 1037 at 1/4 times MIC after 24 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID519142	Antimicrobial activity against non-extended-spectrum beta-lactamase producing Escherichia coli by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID560208	Protein binding in serum of patient with complicated skin and skin structure infection	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID524209	Binding affinity to penicillin-resistant Streptococcus pneumoniae 3413 PBP2X by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID560109	Bactericidal activity against Klebsiella pneumoniae isolate 5427 at 1/4 times MIC after 2 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID496274	Cmax in im dosed rat administered as single dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID543281	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 genomic DNA, pbp2x, pbp1a and pbp2b genes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID523230	Antibacterial activity against Escherichia coli in healthy human intestine assessed as log reduction in bacterial count per gram of feces at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 7	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID535029	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-68 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID564707	Antimicrobial activity against methicillin-resistant, vancomycin-intermediate Staphylococcus aureus 510 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID543284	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2x, pbp2b, murM and Streptococcus pneumoniae 72521 pbp1a genes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID564923	Antimicrobial activity against Penicillin-intermediate Streptococcus pneumoniae s1234 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564907	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae ATCC 49617 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564926	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus sox1 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID368292	Bactericidal activity against methicillin-resistant Staphylococcus aureus SA2 in rabbit endocarditis model at 4 times MIC after 48 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID523234	Antibacterial activity against Bifidobacterium in healthy human intestine assessed as log reduction in bacterial count per gram of feces at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 7	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID564916	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 10 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID368300	Antibacterial activity against Escherichia coli	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID564715	Antimicrobial activity against Penicillin-intermediate Streptococcus pneumoniae s1234 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524200	Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP1A by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID560085	Bactericidal activity against Pseudomonas aeruginosa isolate 796 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID1308267	Antibacterial activity against Staphylococcus aureus COL expressing pbpA antisense plasmid assessed as increase in zone of inhibition after 18 to 20 hrs in presence of xylose	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials.
AID524210	Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP2X by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID543483	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2x, pbp2b, pbp1a and Streptococcus pneumoniae 72521 murM genes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID368306	Antibacterial activity against Pseudomonas aeruginosa	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID564909	Antimicrobial activity against Penicillin-, erythromycin-resistant Streptococcus pneumoniae 37 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID565139	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus ATCC 29213 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560341	Bactericidal activity against Pseudomonas aeruginosa isolate 796 at 1/4 times MIC after 24 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID560339	Bactericidal activity against Escherichia coli isolate 5401 at 1/4 times MIC after 8 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID560322	Bactericidal activity against Pseudomonas aeruginosa isolate 956 at 1/4 times MIC after 4 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID496287	Terminal half life in iv dosed rat administered as single bolus dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID546067	fT>MIC Enterobacteriaceae infected mouse model for 1-log kill	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID522192	Antimicrobial activity against Lactobacillus casei under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID560074	Antimicrobial activity against Enterobacter cloacae isolate 5420 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID524207	Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP2X by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID564706	Antimicrobial activity against methicillin-resistant, vancomycin-resistant Staphylococcus aureus 770 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564698	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae s502 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560202	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID523245	Toxicity against healthy human assessed as effect on hematological parameters at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 9	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID535028	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-51 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID535254	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-2 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID564938	Antimicrobial activity against Penicillin-intermediate Streptococcus pneumoniae s1234 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID535036	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-403 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID543285	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 genomic DNA, pbp2x, pbp1a, pbp2b and Streptococcus pneumoniae 3191 pbp1a genes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID522156	Antimicrobial activity against Fusobacterium mortiferum under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID565154	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus ATCC 29213 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID565144	Antimicrobial activity against methicillin-resistant, vancomycin-intermediate Staphylococcus aureus 510 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560103	Bactericidal activity against Pseudomonas aeruginosa isolate 796 at 1/4 times MIC after 2 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID564939	Antimicrobial activity against Penicillin-, erythromycin-resistant Streptococcus pneumoniae 37 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID563496	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis EF 12704 infected in New Zealand White rabbit assessed as log reduction of bacterial count in aortic valve vegetations at 10 mg/kg, iv administered every 12 hrs for 4 days	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and van
AID565157	Antimicrobial activity against methicillin-resistant, vancomycin-hetroresistant Staphylococcus aureus 618 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID1308269	Antibacterial activity against Staphylococcus aureus COL expressing pbp2 antisense plasmid assessed as increase in zone of inhibition after 18 to 20 hrs in presence of xylose	2016	Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10	Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials.
AID560091	Bactericidal activity against Klebsiella pneumoniae isolate 5427 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID524038	Antibacterial activity against methicillin-, vancomycin-susceptible Staphylococcus aureus ATCC 29213 by macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID523228	Antibacterial activity against Enterococcus in healthy human intestine at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 21	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID524216	Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP2B by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID496292	Tmax in iv dosed rabbit administered as single bolus dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID524034	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae 24 by macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID496297	%T>MIC in Streptococcus pneumoniae-infected neutropenic mouse model	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID560104	Bactericidal activity against Pseudomonas aeruginosa isolate 956 at 1/4 times MIC after 2 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID545822	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.
AID523361	Antibacterial activity against Prevotella by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID564918	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis ATCC 29212 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564723	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 10 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560205	Cmax in healthy human at 600 mg/kg, iv administered as 1 hr infusion every 12 hrs for 14 days measured after first dose	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.
AID496304	Plasma protein binding in human at 600 mg/kg. im administered every 12 hrs	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID496273	AUC (0 to infinity) in im dosed rat administered as single dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID564932	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 20 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560336	Bactericidal activity against Enterobacter cloacae isolate 5420 at 1/4 times MIC after 8 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID560343	Bactericidal activity against Pseudomonas aeruginosa isolate 1019 at 1/4 times MIC after 24 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID524070	Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP4 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID535024	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-23 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID565147	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis ATCC 29212 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564914	Antimicrobial activity against methicillin-resistant, vancomycin-resistant Staphylococcus aureus 770 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524045	Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP1 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID560111	Bactericidal activity against Escherichia coli isolate 5401 at 1/4 times MIC after 2 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID523241	Antibacterial activity against Staphylococcus aureus ATCC 29213 at =< 4 mg/L after 48 hrs by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID563328	Antibacterial activity against vancomycin-resistant Enterococcus faecalis EF NJ1 assessed as bactericidal activity at 20 mg/l after 24 hrs by time kill assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and van
AID564714	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae ATCC 49617 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID563321	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis EF 12704 infected in New Zealand White rabbit assessed as reduction of bacterial count in aortic valve vegetations at 10 mg/kg, administered through ear vein every 12 hrs for 4 da	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and van
AID496284	Tmax in im dosed monkey administered as single dose by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID524057	Binding affinity to methicillin-, vancomycin-resistant, beta-lactamase-positive Staphylococcus aureus 510 PBP2a by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID522145	Antimicrobial activity against Prevotella corporis under anaerobic conditions after 44 hrs by CLSI-M11-47 protocol based agar dilution method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.
AID496277	AUC (0 to infinity) in im dosed rabbit administered as single dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID564705	Antimicrobial activity against methicillin-resistant, vancomycin-hetroresistant Staphylococcus aureus 618 by microdilution method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524037	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae 1076 by macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID564933	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis ATCC 29212 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564732	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus ATCC 29213 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID535258	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-6 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID560334	Bactericidal activity against Pseudomonas aeruginosa isolate 1037 at 1/4 times MIC after 8 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID524211	Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP2A by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID496299	%T>MIC in gram negative bacteria-infected neutropenic mouse model	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID560323	Bactericidal activity against Pseudomonas aeruginosa isolate 1019 at 1/4 times MIC after 4 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID560108	Bactericidal activity against Enterobacter cloacae isolate 5420 at 1/4 times MIC after 2 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID543272	Antimicrobial activity against Streptococcus pneumoniae 72521 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID564934	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 266 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID523247	Antibacterial activity against Peptostreptococcus sp. by broth microdilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID564908	Antimicrobial activity against Penicillin-intermediate Streptococcus pneumoniae s1234 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524047	Binding affinity to methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A PBP1 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID496282	Cmax in im dosed monkey administered as single dose measured after 8 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID560096	Antimicrobial activity against Escherichia coli expressing beta-lactamase inhibitor TEM-1 by agar diffusion method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID564936	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae s502 assessed as time required to induce post antibiotic sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID564713	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae s502 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID535260	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-8 expressing SCCmec element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID524214	Binding affinity to penicillin-resistant Streptococcus pneumoniae 2527 PBP2A by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID543276	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 pbp2x and pbp2b genes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID519145	Antimicrobial activity against Proteus mirabilis by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID565162	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis ATCC 29212 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID496276	Tmax in im dosed rat administered as single dose by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID543482	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 72521 murM, pbp2x, pbp2b and Streptococcus pneumoniae 3191 pbp1a genes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID535034	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-126 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID523243	Antibacterial activity against Escherichia coli ATCC 25922 at =< 4 mg/L after 48 hrs by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID565143	Antimicrobial activity against methicillin-resistant, vancomycin-resistant Staphylococcus aureus 770 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524065	Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP3 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID524054	Binding affinity to methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 PBP2 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID524208	Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP2X by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID535261	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-9 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID523226	Plasma concentration in healthy human at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 5	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID564905	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 609 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID563329	Antibacterial activity against vancomycin-resistant Enterococcus faecalis EF NJ1 infected in New Zealand White rabbit assessed as reduction of bacterial count in aortic valve vegetations at 10 mg/kg, administered through ear vein every 12 hrs for 4 days (	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and van
AID523227	Plasma concentration in healthy human at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 7	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID563327	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis EF 12704 assessed as bactericidal activity at 20 mg/l after 24 hrs by time kill assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and van
AID564935	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 609 assessed as time required to induce sub-MIC effect at 0.3 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID523229	Antifungal activity against Candida albicans in healthy human intestine at 600 mg/kg, iv administered every 12 hrs for 7 days measured on day 21	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Effect of ceftaroline on normal human intestinal microflora.
AID564724	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 20 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524215	Binding affinity to against penicillin-susceptible Streptococcus pneumoniae 1076 PBP2B by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID534780	Antimicrobial activity against community-acquired methicillin-resistant Staphylococcus aureus expressing SCCmec type 4a element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID543278	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2x and Streptococcus pneumoniae 72521 pbp2b genes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID564720	Antimicrobial activity against methicillin-resistant, vancomycin-hetroresistant Staphylococcus aureus 618 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID368301	Antibacterial activity against Klebsiella pneumoniae	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID368293	Bactericidal activity against vancomycin-intermediate Staphylococcus aureus in rabbit endocarditis model at 4 times MIC after 48 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID535019	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-4 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID524056	Binding affinity to methicillin-resistant, heteroresistant vancomycin-intermediate, beta-lactamase-negative Staphylococcus aureus 873 PBP2a by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID560330	Bactericidal activity against Escherichia coli isolate 5411 at 1/4 times MIC after 4 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID543484	Antimicrobial activity against Streptococcus pneumoniae R6 transformed with Streptococcus pneumoniae 3191 pbp2x, pbp2b, pbp1a genes by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
AID564917	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis 20 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID368288	Bactericidal activity against methicillin-resistant Staphylococcus aureus SA2 in rabbit endocarditis model assessed per gram of aortic vegetation at 58 mg/kg infused every 12 hrs for 4 days measured after 48 hrs	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID534783	Bactericidal activity against community-acquired methicillin-resistant Staphylococcus aureus expressing SCCmec type 4a element assessed as antibiotic concentration that reduced the number of viable cells by =>99.9% by colony count method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID524041	Antibacterial activity against methicillin-, linezolid-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 2149A by macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID524042	Antibacterial activity against methicillin-resistant, vancomycin-intermediate, beta-lactamase-positive Staphylococcus aureus 1287 by macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID564716	Antimicrobial activity against Penicillin-, erythromycin-resistant Streptococcus pneumoniae 37 assessed as post antibiotic effect at 10 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID524031	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae 1564 by macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID560331	Bactericidal activity against Pseudomonas aeruginosa isolate 796 at 1/4 times MIC after 8 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID564910	Antimicrobial activity against methicillin-susceptible, vancomycin-susceptible Staphylococcus aureus ATCC 29213 assessed as time required to induce post antibiotic sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560337	Bactericidal activity against Klebsiella pneumoniae isolate 5427 at 1/4 times MIC after 8 hrs by time kill analysis in presence of 4 ug/ml beta-lactamase inhibitor Tazobactam	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID534781	Antimicrobial activity against community-acquired methicillin-resistant Staphylococcus aureus expressing SCCmec type 4 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID368302	Antibacterial activity against Morganella morganii	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
AID564903	Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis ATCC 29212 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID519144	Antimicrobial activity against Morganella morganii by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID535027	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-27 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID524220	Binding affinity to penicillin-resistant Streptococcus pneumoniae 24 PBP3 by competitive binding assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.
AID535022	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-19 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID565158	Antimicrobial activity against methicillin-resistant, vancomycin-resistant Staphylococcus aureus 770 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID565149	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 609 assessed as time required to induce sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID565153	Antimicrobial activity against Penicillin-, erythromycin-resistant Streptococcus pneumoniae 37 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560095	Antimicrobial activity against Escherichia coli expressing beta-lactamase inhibitor CTX-M by agar diffusion method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID565156	Antimicrobial activity against methicillin-resistant, vancomycin-susceptible Staphylococcus aureus vs1 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID496305	%T>MIC human infected with Staphylococcus at 600 mg/kg. im administered every 12 hrs	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.
AID560098	Antimicrobial activity against Escherichia coli expressing beta-lactamase inhibitor SHV-1 by agar diffusion method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID564728	Antimicrobial activity against Penicillin-susceptible Streptococcus pneumoniae s502 assessed as time required to induce sub-MIC effect at 0.2 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
AID560094	Bactericidal activity against Escherichia coli isolate 5411 at 1/4 times MIC after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
AID535026	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-26 expressing SCCmec type 2 element by microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID565163	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 266 assessed as time required to induce post antibiotic sub-MIC effect at 0.4 times MIC after 1 hr by plate counting method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Postantibiotic effect of ceftaroline against gram-positive organisms.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (500)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	25 (5.00)	29.6817
2010's	387 (77.40)	24.3611
2020's	88 (17.60)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	9.23 (24.57)
Research Supply Index	6.33 (2.92)
Research Growth Index	5.55 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (9.23)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	39 (7.51%)	5.53%
Reviews	68 (13.10%)	6.00%
Case Studies	48 (9.25%)	4.05%
Observational	10 (1.93%)	0.25%
Other	354 (68.21%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	5.09	1	1	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
theophylline [no description available]	3.25	1	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
aztreonam Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.. aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.	10.38	19	10
cefuroxime Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.. cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.	2.15	1	0	carbamate ester; cephalosporin
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	4.11	3	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
gentamicin Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.	4.71	9	0
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	2.46	2	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	2.06	1	0	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	3.25	1	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	2.15	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	3.14	5	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	2.6	1	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
cephalothin Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.	2.15	1	0	azabicycloalkene; beta-lactam antibiotic allergen; carboxylic acid; cephalosporin; semisynthetic derivative; thiophenes	antibacterial drug; antimicrobial agent
adenosine monophosphate Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.	2.41	1	0	adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
methicillin Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.	10.62	20	0	penicillin allergen; penicillin	antibacterial drug
cloxacillin Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.	2.6	1	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial agent; antibacterial drug
oxacillin Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.	3.61	8	0	penicillin	antibacterial agent; antibacterial drug
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	3.93	11	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	2.1	1	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
penicillin v Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.	2.05	1	0	penicillin allergen; penicillin
penicillanic acid Penicillanic Acid: A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed). penicillanic acid : A penam that consists of 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane bearing a carboxy group at position 2 and having (2S,5R)-configuration.	3.25	1	0	penicillanic acids
nafcillin Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.	2.9	3	0	penicillin allergen; penicillin	antibacterial drug
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.07	1	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	4.81	5	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazoles [no description available]	2.07	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
ephedrine Ephedrine: A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.. (-)-ephedrine : A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively.	3.25	1	0	phenethylamine alkaloid; phenylethanolamines	bacterial metabolite; environmental contaminant; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	2.07	1	0
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	3.58	8	0	cyclic ketone; erythromycin
deoxycytidine [no description available]	5.09	1	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	20.16	89	11	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
floxacillin Floxacillin: Antibiotic analog of CLOXACILLIN.. flucloxacillin : A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.	2.72	2	0	penicillin allergen; penicillin	antibacterial drug
acetylglucosamine Acetylglucosamine: The N-acetyl derivative of glucosamine.. N-acetyl-beta-D-glucosamine : An N-acetyl-D-glucosamine having beta-configuration at the anomeric centre.	2.04	1	0	N-acetyl-D-glucosamine	epitope
trolamine salicylate Arthritis: Acute or chronic inflammation of JOINTS.	2.52	2	0
cefazolin Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.	3.31	5	0	beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles	antibacterial drug
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	2.98	4	0	penicillin allergen; penicillin	antibacterial drug
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	2.05	1	0	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	5.09	1	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	2.05	1	0	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
piperacillin Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.	2.52	2	0	penicillin allergen; penicillin	antibacterial drug
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	5.09	1	1	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	2.25	1	0	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	27.12	511	51	cephalosporin	fungal metabolite
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	3.25	1	0	1,2,3-triazole
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	5.09	1	1	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
doripenem Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.	3.14	1	0	carbapenems
oxazolidin-2-one Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.	7.21	14	0	carbamate ester; oxazolidinone	metabolite
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	2.78	3	0
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	3.59	8	0	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
tazobactam Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.	5.68	4	0	penicillanic acids; triazoles	antiinfective agent; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
sulbactam [no description available]	2.13	1	0	penicillanic acids
carbapenems [no description available]	7.21	8	1
beta-lactams 2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.	6.69	15	1	beta-lactam antibiotic allergen; beta-lactam
proline Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.	2.07	1	0	amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid	algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	3.87	11	0	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
ertapenem Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.	3.1	4	0	carbapenemcarboxylic acid; pyrrolidinecarboxamide	antibacterial drug
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	4.14	3	1	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	2.07	1	0
trimethoprim, sulfamethoxazole drug combination Trimethoprim, Sulfamethoxazole Drug Combination: A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.. co-trimoxazole : A two-component mixture comprising trimethoprim and sulfamethoxazole.	4.32	5	0
acetogenins Acetogenins: Polyketides of up to a few dozen carbons in length, formed by chain extension of multiple PROPIONATES and oxygenated to form tetrahydrofuran and lactone rings along the length of the chain. They are found in ANNONACEAE and other PLANTS. Related compounds cyclize to MACROLIDES.	5.09	1	1
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	3.37	6	0	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
cefoxitin Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.	2.59	2	0	beta-lactam antibiotic allergen; cephalosporin; cephamycin; semisynthetic derivative	antibacterial drug
linezolid [no description available]	12.86	36	0	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
eicosapentaenoic acid icosapentaenoic acid : Any straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds.. all-cis-5,8,11,14,17-icosapentaenoic acid : An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.	5.09	1	1	icosapentaenoic acid; omega-3 fatty acid	anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical
mupirocin Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.	2.78	3	0	alpha,beta-unsaturated carboxylic ester; epoxide; monocarboxylic acid; oxanes; secondary alcohol; triol	antibacterial drug; bacterial metabolite; protein synthesis inhibitor
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	4.99	11	0
fosfomycin Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.	2.69	2	0	epoxide; phosphonic acids	antimicrobial agent; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
sesquiterpenes [no description available]	5.09	1	1
clavulanic acid Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.	2.48	2	0	oxapenam	antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor
cefuroxime [no description available]	2.45	2	0	3-(carbamoyloxymethyl)cephalosporin; furans; oxime O-ether	drug allergen
ceftriaxone [no description available]	4.85	10	0	1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	3.47	7	0	cephalosporin; oxime O-ether	antibacterial drug
ceftazidime [no description available]	3.55	2	0	cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
cefotaxime Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.	2.97	4	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen
aztreonam [no description available]	2.05	1	0	beta-lactam antibiotic allergen; monobactam	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
vilazodone hydrochloride [no description available]	2.07	1	0	hydrochloride	antidepressant; serotonergic agonist; serotonin uptake inhibitor
amoxicillin-potassium clavulanate combination Amoxicillin-Potassium Clavulanate Combination: A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.	2.05	1	0
gentamicin sulfate [no description available]	2.04	1	0
fidaxomicin Fidaxomicin: A narrow-spectrum macrolide antibacterial agent that is used in the treatment of diarrhea associated with CLOSTRIDIUM DIFFICILE INFECTION.. fidaxomicin : An 18-membered macrolide that is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. A narrow spectrum antibiotic used for treatment of Clostridium difficile-related infections.	2.07	1	0
linagliptin Linagliptin: A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.. linagliptin : A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes.	2.07	1	0	aminopiperidine; quinazolines	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent
me1036 ME1036: structure in first source	3.55	2	0
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	2.07	1	0
sm-216601 SM-216601: exhibits potent activity against methicillin-resistant staphylococci (MRS) and vancomycin-resistant enterococci (VRE); structure in first source	3.14	1	0
lurasidone hydrochloride Lurasidone Hydrochloride: A thiazole derivative and atypical ANTIPSYCHOTIC AGENT that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST; SEROTONIN 5-HT2 RECEPTOR ANTAGONIST, serotonin 5-HT7 receptor antagonist, and antagonist of the adrenergic α2A and α2C receptors, as well as a partial SEROTONIN 5-HT1A RECEPTOR AGONIST. It is used in the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER.. lurasidone hydrochloride : A hydrochloride obtained by reaction of lurasidone with one equivalent of hydrochloric acid. An atypical antipsychotic agent used for the treatment of schizophrenia.	2.07	1	0	hydrochloride	adrenergic antagonist; dopaminergic antagonist; second generation antipsychotic; serotonergic antagonist
technetium tc 99m exametazime Technetium Tc 99m Exametazime: A gamma-emitting RADIONUCLIDE IMAGING agent used in the evaluation of regional cerebral blood flow and in non-invasive dynamic biodistribution studies and MYOCARDIAL PERFUSION IMAGING. It has also been used to label leukocytes in the investigation of INFLAMMATORY BOWEL DISEASES.	5.09	1	1
virginiamycin Virginiamycin: A cyclic polypeptide antibiotic complex from Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. It consists of 2 major components, VIRGINIAMYCIN FACTOR M1 and virginiamycin Factor S1. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.. virginiamycin : A mixture of cyclic polypeptide streptogramin antibiotics produced by Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. The two major components are virginiamycin M1 (also known as pristinamycin IIA) and virginiamycin S1. Virginiamycin has been widely used as a growth promotion agent in livestock and has been to have bacteriostatic activity against Gram-positive organisms such as staphylococci and streptococci.	3.91	3	0
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.11	1	0
ly-146032 [no description available]	2.98	4	0	heterodetic cyclic peptide; lipopeptide antibiotic; lipopeptide; macrocycle; macrolide	antibacterial drug; bacterial metabolite; calcium-dependent antibiotics
chlorophyll a Chlorophyll: Porphyrin derivatives containing magnesium that act to convert light energy in photosynthetic organisms.. chlorophyll : A family of magnesium porphyrins, defined by the presence of a fifth ring beyond the four pyrrole-like rings. The rings can have various side chains which usually include a long phytol chain.	5.09	1	1	chlorophyll; methyl ester	cofactor
ro13-9904 Ceftriaxone: A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.. ceftriaxone : A third-generation cephalosporin compound having 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetylamino and [(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl side-groups.	14.58	42	15
piperacillin, tazobactam drug combination Piperacillin, Tazobactam Drug Combination: An antibiotic combination product of piperacillin and tazobactam, a penicillanic acid derivative with enhanced beta-lactamase inhibitory activity, that is used for the intravenous treatment of intra-abdominal, pelvic, and skin infections and for community-acquired pneumonia of moderate severity. It is also used for the treatment of PSEUDOMONAS AERUGINOSA INFECTIONS.	3.35	1	0
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.13	1	0
colistin Colistin: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.. colistin : A multi-component mixture comprising mostly of colistin A (R = Me) and B (R = H), with small amounts of colistin C and other polymyxins, produced by certain strains of Bacillus polymyxa var. colistinus. An antibiotic, it is used as its sulfate salt (for oral or topical use) or as the sodium salt of the N-methylsulfonic acid derivative (the injectable form) in the treatment of severe Gram-negative infections, partiularly those due to Pseudomonas aeruginosa.	2.41	1	0
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	3.19	5	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	4.57	7	0
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.13	1	0	benzenes; hydroxycoumarin; methyl ketone
tigecycline [no description available]	4.9	10	0
caseins Caseins: A mixture of related phosphoproteins occurring in milk and cheese. The group is characterized as one of the most nutritive milk proteins, containing all of the common amino acids and rich in the essential ones.	5.09	1	1
daptomycin [no description available]	10.69	70	0
pheophytin a pheophytin a: structure given in first source; RN given refers to (3S-(3alpha(2E,7S,11S),4beta,21beta))-isomer	5.09	1	1
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	6.91	10	1	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor

Condition	Indicated	Relationship Strength	Studies	Trials
Infections, Staphylococcal [description not available]	0	20.18	251	43
Bacterial Endocarditides [description not available]	0	7.17	22	0
Endocarditis, Bacterial Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.	0	7.17	22	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	0	20.18	251	43
Community Acquired Infection [description not available]	0	19.68	129	23
Infections, Pneumococcal [description not available]	0	3.58	8	0
Pneumococcal Infections Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.	0	3.58	8	0
Bacterial Disease [description not available]	0	8.34	19	1
Bacterial Infections Infections by bacteria, general or unspecified.	1	10.34	19	1
Communicable Diseases, Emerging Infectious diseases that are novel in their outbreak ranges (geographic and host) or transmission mode.	0	2.05	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	4.87	12	0
Primary Peritonitis [description not available]	0	2.13	1	0
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	0	2.13	1	0
Extravascular Hemolysis [description not available]	0	2.15	1	0
Bacterial Infections, Gram-Negative [description not available]	0	3.48	7	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	0	2.15	1	0
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	0	3.48	7	0
Infections, Soft Tissue [description not available]	0	18.49	101	10
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	0	15.73	53	2
Pneumonia Infection of the lung often accompanied by inflammation.	1	17.73	53	2
Soft Tissue Infections Infections of non-skeletal tissue, i.e., exclusive of bone, ligaments, cartilage, and fibrous tissue. The concept is usually referred to as skin and soft tissue infections and usually subcutaneous and muscle tissue are involved. The predisposing factors in anaerobic infections are trauma, ischemia, and surgery. The organisms often derive from the fecal or oral flora, particularly in wounds associated with intestinal surgery, decubitus ulcer, and human bites. (From Cecil Textbook of Medicine, 19th ed, p1688)	0	18.49	101	10
Bacterial Pneumonia [description not available]	0	16.31	57	16
Pneumonia, Bacterial Inflammation of the lung parenchyma that is caused by bacterial infections.	1	18.31	57	16
Acute Kidney Failure [description not available]	0	5.2	2	1
Critical Illness A disease or state in which death is possible or imminent.	0	3.21	4	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	0	5.2	2	1
Infective Endocarditis [description not available]	0	4.64	8	0
Endocarditis Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening.	0	4.64	8	0
Bacteremia The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.	0	17.08	82	5
Cystic Fibrosis of Pancreas [description not available]	0	5.88	7	1
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	0	5.88	7	1
Endotoxin Shock [description not available]	0	5.25	3	1
Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.	0	5.25	3	1
Experimental Pneumococcal Meningitis [description not available]	0	2.59	2	0
Meningitis, Pneumococcal An acute purulent infection of the meninges and subarachnoid space caused by Streptococcus pneumoniae, most prevalent in children and adults over the age of 60. This illness may be associated with OTITIS MEDIA; MASTOIDITIS; SINUSITIS; RESPIRATORY TRACT INFECTIONS; sickle cell disease (ANEMIA, SICKLE CELL); skull fractures; and other disorders. Clinical manifestations include FEVER; HEADACHE; neck stiffness; and somnolence followed by SEIZURES; focal neurologic deficits (notably DEAFNESS); and COMA. (From Miller et al., Merritt's Textbook of Neurology, 9th ed, p111)	0	2.59	2	0
Kidney Failure A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.	0	5.76	6	1
Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.	0	5.76	6	1
Black Fever [description not available]	0	2.6	1	0
Leishmaniasis, Visceral A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.	0	2.6	1	0
Pyoderma Any purulent skin disease (Dorland, 27th ed).	0	2.6	1	0
Tuberculosis, Drug-Resistant [description not available]	0	4.91	1	1
Cholangiocellular Carcinoma [description not available]	0	4.91	1	1
Blood Poisoning [description not available]	0	8.84	10	4
Alcohol Abuse [description not available]	0	4.91	1	1
Asthma, Bronchial [description not available]	0	4.91	1	1
Bile Duct Cancer [description not available]	0	4.91	1	1
Disorder, Borderline Personality [description not available]	0	4.91	1	1
Brucella Infection [description not available]	0	4.91	1	1
E coli Infections [description not available]	0	4.94	2	1
Reproductive Sterility [description not available]	0	4.91	1	1
Innate Inflammatory Response [description not available]	0	4.91	1	1
Cirrhosis, Liver [description not available]	0	4.91	1	1
Cancer of Pancreas [description not available]	0	4.91	1	1
Acute Edematous Pancreatitis [description not available]	0	4.91	1	1
As If Personality [description not available]	0	4.91	1	1
Cancer of Stomach [description not available]	0	4.91	1	1
Koch's Disease [description not available]	0	4.91	1	1
Local Neoplasm Recurrence [description not available]	0	4.91	1	1
Acute Disease Disease having a short and relatively severe course.	0	7.21	7	3
Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)	0	4.91	1	1
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	0	4.91	1	1
Ascites Accumulation or retention of free fluid within the peritoneal cavity.	0	4.91	1	1
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	0	4.91	1	1
Bile Duct Neoplasms Tumors or cancer of the BILE DUCTS.	0	4.91	1	1
Borderline Personality Disorder A personality disorder marked by a pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts. (DSM-IV)	0	4.91	1	1
Brucellosis Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss.	0	4.91	1	1
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	0	4.94	2	1
Infertility A reduced or absent capacity to reproduce.	0	4.91	1	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	4.91	1	1
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	0	4.91	1	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	0	6.84	4	2
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	0	4.91	1	1
Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.	0	4.91	1	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	7.96	5	4
Stomach Neoplasms Tumors or cancer of the STOMACH.	0	4.91	1	1
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	0	4.91	1	1
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	1	6.91	1	1
Tuberculosis, Multidrug-Resistant Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.	0	4.91	1	1
Cholangiocarcinoma A malignant tumor arising from the epithelium of the BILE DUCTS.	0	4.91	1	1
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	1	10.84	10	4
Neonatal Early-Onset Sepsis [description not available]	0	5.07	2	1
Neonatal Sepsis Blood infection that occurs in an infant younger than 90 days old. Early-onset sepsis is seen in the first week of life and most often appears within 24 hours of birth. Late-onset occurs after 1 week and before 3 months of age.	0	5.07	2	1
Adverse Drug Event [description not available]	0	9.41	7	4
Staphylococcal Pneumonia [description not available]	0	5.69	12	0
Pneumonia, Staphylococcal Pneumonia caused by infections with bacteria of the genus STAPHYLOCOCCUS, usually with STAPHYLOCOCCUS AUREUS.	0	5.69	12	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	9.41	7	4
Bacterial Skin Diseases [description not available]	0	16.16	72	17
Skin Diseases, Bacterial Skin diseases caused by bacteria.	0	16.16	72	17
Brain Disorders [description not available]	0	2.25	1	0
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	0	2.25	1	0
Infection, Postoperative Wound [description not available]	0	3.22	5	0
Pachymeningitis [description not available]	0	3.77	3	0
Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)	1	5.77	3	0
Bacterial Infections, Gram-Positive [description not available]	0	6.44	14	1
Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.	0	6.44	14	1
Osteomyelitis INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.	0	3.64	8	0
Infections, Respiratory [description not available]	0	3.84	10	0
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	0	3.84	10	0
Cronobacter Infections [description not available]	0	4.72	10	0
Enterobacteriaceae Infections Infections with bacteria of the family ENTEROBACTERIACEAE.	0	4.72	10	0
2019 Novel Coronavirus Disease [description not available]	0	2.31	1	0
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available]	0	2.31	1	0
Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	0	2.31	1	0
Infectious Diseases [description not available]	0	2.6	1	0
Communicable Diseases An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.	0	2.6	1	0
Allergy, Drug [description not available]	0	3.04	4	0
Atopic Hypersensitivity [description not available]	0	2.31	1	0
Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.	0	3.04	4	0
Pleuropericarditis Inflammation of both the PERICARDIUM and the PLEURA.	0	2.55	2	0
Pericarditis Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS.	0	2.55	2	0
Infections, Prosthesis-Related [description not available]	0	4.89	7	1
Mycoplasma dispar Infection [description not available]	0	2.15	1	0
Chlamydial Pneumonia Pneumonia caused by infections with the genus CHLAMYDIA; and CHLAMYDOPHILA, usually with CHLAMYDOPHILA PNEUMONIAE.	0	2.15	1	0
Infections, Staphylococcal Skin [description not available]	0	11.9	39	1
Staphylococcal Skin Infections Infections to the skin caused by bacteria of the genus STAPHYLOCOCCUS.	0	11.9	39	1
Bone Diseases, Infectious Bone diseases caused by pathogenic microorganisms.	0	2.52	2	0
Arthropathies [description not available]	0	2.15	1	0
Joint Diseases Diseases involving the JOINTS.	0	2.15	1	0
Caries, Dental [description not available]	0	2.15	1	0
Empyema, Thoracic [description not available]	0	2.15	1	0
Group A Strep Infection [description not available]	0	3.19	5	0
Dental Caries Localized destruction of the tooth surface initiated by decalcification of the enamel followed by enzymatic lysis of organic structures and leading to cavity formation. If left unchecked, the cavity may penetrate the enamel and dentin and reach the pulp.	0	2.15	1	0
Streptococcal Infections Infections with bacteria of the genus STREPTOCOCCUS.	0	3.19	5	0
Empyema, Pleural Suppurative inflammation of the pleural space.	0	2.15	1	0
Exanthem [description not available]	0	2.17	1	0
Allergic Reaction [description not available]	0	2.17	1	0
Exanthema Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.	0	2.17	1	0
Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	0	2.17	1	0
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	0	3.72	9	0
DRESS Syndrome [description not available]	0	2.15	1	0
Carditis [description not available]	0	2.15	1	0
Chylopericardium [description not available]	0	2.15	1	0
Complication, Postoperative [description not available]	0	3.76	3	0
Myocarditis Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.	0	2.15	1	0
Pericardial Effusion Fluid accumulation within the PERICARDIUM. Serous effusions are associated with pericardial diseases. Hemopericardium is associated with trauma. Lipid-containing effusion (chylopericardium) results from leakage of THORACIC DUCT. Severe cases can lead to CARDIAC TAMPONADE.	0	2.15	1	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	0	3.76	3	0
Infant, Premature, Diseases Diseases that occur in PREMATURE INFANTS.	0	2.17	1	0
Pneumonia, Pneumococcal A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.	0	8.21	9	4
Spinal Diseases Diseases involving the SPINE.	0	2.17	1	0
Ventilator-Associated Pneumonia [description not available]	0	3.46	2	0
Health Care Associated Infection [description not available]	0	6.21	21	0
Cross Infection Any infection which a patient contracts in a health-care institution.	0	6.21	21	0
Pneumonia, Ventilator-Associated Serious INFLAMMATION of the LUNG in patients who required the use of PULMONARY VENTILATOR. It is usually caused by bacterial CROSS INFECTION in hospitals.	0	3.46	2	0
Bacterial Meningitides [description not available]	0	4.14	5	0
Cerebral Ventriculitis Inflammation of CEREBRAL VENTRICLES.	0	3.12	1	0
Meningitis, Bacterial Bacterial infections of the leptomeninges and subarachnoid space, frequently involving the cerebral cortex, cranial nerves, cerebral blood vessels, spinal cord, and nerve roots.	0	4.14	5	0
Inflammatory Response Syndrome, Systemic [description not available]	0	9.71	13	4
Systemic Inflammatory Response Syndrome A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever	1	11.71	13	4
Benign Neoplasms [description not available]	0	2.21	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	2.21	1	0
Hospital Acquired Pneumonia [description not available]	0	3.12	1	0
Healthcare-Associated Pneumonia Infection of the lung often accompanied by inflammation that is acquired through an interaction within a healthcare institution often through a therapeutic experience (e.g., use of catheters or ventilators).	0	3.12	1	0
Clostridioides difficile Infection [description not available]	0	2.08	1	0
Clostridium Infections Infections with bacteria of the genus CLOSTRIDIUM and closely related CLOSTRIDIOIDES species.	0	2.08	1	0
Arthritides, Bacterial [description not available]	0	3.7	3	0
Complications of Diabetes Mellitus [description not available]	0	2.08	1	0
Foot Diseases Anatomical and functional disorders affecting the foot.	0	2.08	1	0
Eosinophilia, Pulmonary [description not available]	0	2.49	2	0
Pulmonary Eosinophilia A condition characterized by infiltration of the lung with EOSINOPHILS due to inflammation or other disease processes. Major eosinophilic lung diseases are the eosinophilic pneumonias caused by infections, allergens, or toxic agents.	0	2.49	2	0
Infectious Skin Diseases [description not available]	0	6.27	5	1
Skin Diseases, Infectious Skin diseases caused by bacteria, fungi, parasites, or viruses.	0	6.27	5	1
Escherichia coli Meningitis [description not available]	0	2.08	1	0
Infections, Klebsiella [description not available]	0	3.01	4	0
Klebsiella Infections Infections with bacteria of the genus KLEBSIELLA.	0	3.01	4	0
Co-infection [description not available]	0	2.08	1	0
Electrocardiogram QT Prolonged [description not available]	0	4.4	1	1
Long QT Syndrome A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.	0	4.4	1	1
Chronic Kidney Diseases [description not available]	0	2.1	1	0
Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)	0	2.1	1	0
Anterior Cervical Pain [description not available]	0	2.1	1	0
Thrombopenia [description not available]	0	2.1	1	0
Abscess, Epidural [description not available]	0	2.1	1	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	0	2.1	1	0
Neck Pain Discomfort or more intense forms of pain that are localized to the cervical region. This term generally refers to pain in the posterior or lateral regions of the neck.	0	2.1	1	0
Chronic Kidney Failure [description not available]	0	5.66	3	2
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	0	3.48	1	1
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	0	5.66	3	2
Airflow Obstruction, Chronic [description not available]	0	2.1	1	0
Anoxemia [description not available]	0	2.1	1	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	0	2.1	1	0
Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.	0	2.1	1	0
Polyarthritis [description not available]	0	2.52	2	0
Arthritis Acute or chronic inflammation of JOINTS.	0	2.52	2	0
Blood Diseases [description not available]	0	3.01	1	0
Hematologic Diseases Disorders of the blood and blood forming tissues.	0	3.01	1	0
Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).	0	2.51	2	0
Interstitial Nephritis [description not available]	0	2.1	1	0
Nephritis, Interstitial Inflammation of the interstitial tissue of the kidney. This term is generally used for primary inflammation of KIDNEY TUBULES and/or surrounding interstitium. For primary inflammation of glomerular interstitium, see GLOMERULONEPHRITIS. Infiltration of the inflammatory cells into the interstitial compartment results in EDEMA, increased spaces between the tubules, and tubular renal dysfunction.	0	2.1	1	0
Infections, Pseudomonas [description not available]	0	3.39	2	0
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	0	3.39	2	0
Diabetic Feet [description not available]	0	2.52	2	0
Overweight A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.	0	2.11	1	0
Diabetic Foot Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.	0	2.52	2	0
Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.	0	2.5	2	0
Femur Neck Fractures [description not available]	0	2.1	1	0
Femoral Neck Fractures Fractures of the short, constricted portion of the thigh bone between the femur head and the trochanters. It excludes intertrochanteric fractures which are HIP FRACTURES.	0	2.1	1	0
Aneurysm, False Not an aneurysm but a well-defined collection of blood and CONNECTIVE TISSUE outside the wall of a blood vessel or the heart. It is the containment of a ruptured blood vessel or heart, such as sealing a rupture of the left ventricle. False aneurysm is formed by organized THROMBUS and HEMATOMA in surrounding tissue.	0	2.11	1	0
Deep Vein Thrombosis [description not available]	0	2.11	1	0
Fungal Diseases [description not available]	0	2.11	1	0
Mycoses Diseases caused by FUNGI.	0	2.11	1	0
Venous Thrombosis The formation or presence of a blood clot (THROMBUS) within a vein.	0	2.11	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	4.41	1	1
Morbid Obesity [description not available]	0	4.41	1	1
Obesity, Morbid The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.	0	4.41	1	1
Fournier Disease [description not available]	0	2.11	1	0
Aortic Valve Disease 1 [description not available]	0	2.11	1	0
Abnormality, Heart [description not available]	0	2.11	1	0
Heart Valve Diseases Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).	0	2.52	2	0
Bicuspid Aortic Valve Disease Congenital heart valve defects where the AORTIC VALVE has two instead of normal three cusps. It is often associated with AORTIC REGURGITATION and AORTIC INSUFFICIENCY.	0	2.11	1	0
Heart Defects, Congenital Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.	0	2.11	1	0
Catheter-Associated Infections [description not available]	0	2.52	2	0
Infection, Wound [description not available]	0	2.11	1	0
Discitis Inflammation of an INTERVERTEBRAL DISC or disk space which may lead to disk erosion. Until recently, discitis has been defined as a nonbacterial inflammation and has been attributed to aseptic processes (e.g., chemical reaction to an injected substance). However, recent studies provide evidence that infection may be the initial cause, but perhaps not the promoter, of most cases of discitis. Discitis has been diagnosed in patients following discography, myelography, lumbar puncture, paravertebral injection, and obstetrical epidural anesthesia. Discitis following chemonucleolysis (especially with chymopapain) is attributed to chemical reaction by some and to introduction of microorganisms by others.	0	2.11	1	0
Breathlessness [description not available]	0	2.13	1	0
Dyspnea Difficult or labored breathing.	0	2.13	1	0
Spondylitis Inflammation of the SPINE. This includes both arthritic and non-arthritic conditions.	0	2.13	1	0
Hospital-Acquired Condition [description not available]	0	3.04	1	0
Abscess, Abdominal [description not available]	0	3.04	1	0
Abdominal Abscess An abscess located in the abdominal cavity, i.e., the cavity between the diaphragm above and the pelvis below. (From Dorland, 27th ed)	0	3.04	1	0
Bronchiolitis Inflammation of the BRONCHIOLES.	0	2.13	1	0
Arthritis, Degenerative [description not available]	0	2.13	1	0
Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.	0	2.13	1	0
Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.	0	2.15	1	0
Foreign Bodies Inanimate objects that become enclosed in the body.	0	2.13	1	0
Rodent Diseases Diseases of rodents of the order RODENTIA. This term includes diseases of Sciuridae (squirrels), Geomyidae (gophers), Heteromyidae (pouched mice), Castoridae (beavers), Cricetidae (rats and mice), Muridae (Old World rats and mice), Erethizontidae (porcupines), and Caviidae (guinea pigs).	0	2.06	1	0
Genome Instability [description not available]	0	2.07	1	0
Bites [description not available]	0	2.07	1	0
Antibiotic-Associated Colitis [description not available]	0	2.07	1	0
Enterocolitis, Pseudomembranous An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.	0	2.07	1	0
Respiratory Tract Diseases Diseases involving the RESPIRATORY SYSTEM.	0	2.03	1	0
Recrudescence [description not available]	0	3.42	1	1

chemdatabank.com